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Mycobacterium tuberculosis is a pathogenic organism that infects a third of the 
world’s population and causes approximately 2 million deaths per year. This pathogen is a 
member of the Mycobacterium tuberculosis complex (MTBC) which constitutes eleven 
members that share 99.9% similarity at nucleotide level and have near identical 16S rRNA. 
MTBC members cause Tuberculosis in a variety of host species. M. bovis and M. caprae 
form part of the animal-adapted MTBC members that cause disease in a variety of animal 
hosts (primarily bovidae) and goats, respectively. Extensive genetic analyses have been done 
to try and explain virulence, phenotype and host-preferences of these members with no 
success. Recent advances in mass spectrometry techniques enable us to analyse thousands of 
proteins simultaneously and explore the possible proteomic variation between these members 
that could contribute to the phenotypic, virulence and host-specificity characteristics of the 
MTBC members. 
In this study, we aimed to characterize the proteomes of M. bovis and M. caprae by 
analysing the high and or low abundance proteins, relative to M. tuberculosis H37Rv, which 
could possibly explain virulence mechanisms and host-specificity of these MTBC members. 
Whole cell lysate protein extracts were extracted from mid-log phase cultures of                   
M. tuberculosis H37Rv (A600 = 0.7), M. bovis (A600 = 0.65) and M. caprae (A600 = 0.7). 
Proteins were fractionated by SDS-PAGE and in gel reduction/alkylation and trypsin digests 
were done. Peptides were identified using LC-MS/MS on the Orbitrap Velos mass 
spectrometer and their corresponding proteins were identified by searching peptide databases. 
Protein functional groups were assigned according to TubercuList. To provide an integrated 
overview of the overall network of protein expression (rather than just limit analysis to 
individual proteins), pathway analysis was done on the differentially expressed proteins of   




M. bovis and M. caprae using PATRIC (Pathosystems Resource Integration Center) and 
pathways were visualized using iTUBY (Interactive Pathway Explorer database).  
We detected 2199, 2367 and 2350 proteins for M. tuberculosis H37Rv, M. bovis and 
M. caprae which correlate to 60% of the proposed M. tuberculosis proteins being expressed 
during log-phase. Considering similarities between genomes, it was no surprise that the 
functional distribution of the detected proteins extracted was similar. Metabolic pathways 
affected by the proteins which were in higher abundance in M. bovis and M. caprae included 
amino acid and lipid metabolism, oxidative phosphorylation and xenobiotic degradation. The 
over-abundant proteins in M. bovis and M. caprae were also involved in ribosomal proteins 
and carbohydrate metabolism, respectively. Lower abundance proteins in these species were 
found in lipid and pyrimidine metabolism. These affected pathways can be associated with 
the ability of M. bovis and M. caprae to adapt to their environment more readily which helps 
them to survive inside the hosts and cause severe pathogenesis.  
In this study the proteomes of M. tuberculosis H37Rv, M. bovis and M. caprae were 
characterized and the variation between detected proteins and protein abundances explored in 
order to describe differences between these closely related strains. Future research on animal-
adapted Mycobacterial species will address knowledge gaps that are needed to prevent 
transmission and spread of the disease. Understanding the mechanisms of virulence and 
pathogenicity could lead to development of efficient vaccines and diagnostic tests for a 
variety of animal hosts.   





Mycobacterium tuberculosis is 'n patogene organisme wat 'n derde van die wêreld se 
bevolking infekteer en veroorsaak ongeveer 2 miljoen sterftes per jaar. Hierdie patogeen is 'n 
lid van die Mycobacterium tuberculosis kompleks (MTBK) wat bestaan uit elf lede wat 
99,9% ooreenkoms op nukleotiedvlak toon en amper identiese 16S rRNA deel. MTBK lede 
veroorsaak Tuberkulose in 'n verskeidenheid van gasheerspesies. M. bovis en M. caprae vorm 
deel van die MTBK en veroorsaak Tuberkulose in 'n verskeidenheid van diere-gashere 
(hoofsaaklik Bovidae) en bokke, onderskeidelik. Verskeie genetiese ontledings is al gedoen 
om virulensie, fenotipe en gasheer-voorkeure van hierdie lede te ondersoek, maar was 
onsuksesvol. Die onlangse vooruitgang in massa-spektrometriese tegnieke stel ons in staat 
om duisende proteïene gelyktydig te analiseer en die moontlike proteomiese variasie tussen 
hierdie lede te identifiseer. Proteomiese analises kan bydra tot die fenotipiese-, virulensie- en 
gasheer-spesifieke eienskappe van die hierdie lede. 
Die doel met hierdie studie was om die proteome van M. bovis en M. caprae te 
beskryf deur die proteïene te identifiseer wat differentieel uitgedruk was, in vergelyking met 
M. tuberculosis H37Rv, wat moontlik die virulensie meganismes en gasheer-spesifisiteit van 
hierdie MTBK lede kan verduidelik. Proteïen ekstraksies is geneem uit die middel-
logaritmiese groeifase van M. tuberculosis H37Rv (A600 = 0.7), M. bovis (A600 = 0,65) en     
M. caprae (A600 = 0,7) kulture. Proteïene is gefraksioneer deur SDS-PAGE en in-jel 
vermindering/alkilering en tripsien vertering is gedoen. Peptiede is geïdentifiseer met behulp 
van LC-MS/MS op die Orbitrap Velos massa-spektrometer en die ooreenstemmende 
proteïene is geïdentifiseer. Proteïen funksionele groepe is toegeken aan proteïene volgens 
TubercuList. Om ‘n geïntegreerde oorsig van die totale netwerk van die proteïen uitdrukking 
te gee (eerder as ontleding van slegs individuele proteïene), is metaboliese weë analises op 
die differensieel uitgedrukte proteïene van M. bovis en M. caprae gedoen, deur gebruik te 




maak van PATRIC (Pathosystems Resource Integration Center). Metaboliese weë is 
gevisualiseer deur iTUBY (Interactive Pathway Explorer databasis). 
‘n Totaal van 2199, 2367 en 2350 proteïene is ontdek vir M. tuberculosis H37Rv,     
M. bovis en M. caprae onderskeidelik, wat ooreenstem met 60% van die voorgestelde          
M. tuberculosis proteïene. A.g.v. genoom ooreenkomste, was dit geen verrassing dat die 
funksionele verspreiding van die proteïene soortgelyk was nie. Metaboliese weë wat geraak 
word deur die proteïene wat in hoë-oorvloed in M. bovis en M. caprae ontdek is, sluit die 
aminosuur- en lipiedmetabolisme, oksidatiewe fosforilering en xenobiotiese afbreking in. Die 
hoë-oorvloed proteïene in M. bovis en M. caprae is ook betrokke by ribosomale funksies en 
koolhidraatmetabolisme, onderskeidelik. Proteiene wat in laer-oorvloed in hierdie twee 
spesies geidentifiseer is, speel ‘n rol in lipied- en pirimidienmetabolisme Geaffekteerde 
metaboliese weë kan geassosieer word met die vermoë van M. bovis en M. caprae om meer 
geredelik by hul omgewing aan te pas wat die organimses help om te oorleef in die gasheer 
en patogenese te ontwikkel. 
In hierdie studie is die proteome van M. tuberculosis H37Rv, M. bovis en M. caprae 
beskryf en die variasie tussen die ontdekte proteïene en proteïen verspreidings ontleed om die 
verskille tussen hierdie nou verwante spesies te beskryf. Toekomstige navorsing op diere-
aangepaste mikobakteriële spesies sal die kennisgapings oorbrug wat nodig is om die oordrag 
en verspreiding van Tuberkulose te voorkom. Begrip van die meganismes van virulensie en 
patogenisiteit kan lei tot die ontwikkeling van doeltreffende entstowwe en diagnostiese toetse 
vir 'n verskeidenheid van diere-gashere. 
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In 1993, a global emergency was declared by the World Health Organization (WHO) 
because tuberculosis (TB) was epidemic in many areas of the world. Now, two decades later, 
TB remains an important public health problem that results in millions of deaths each year 
(World Health Organization). Zoonotic TB is present in animals in most developing countries 
where surveillance and control activities are often inadequate or unavailable; therefore, 
animal tuberculosis can have devastating effects on national economy and agricultural 
industries (Cosivi, Grange et al. 1998). 
Tuberculosis is caused in different hosts by different members of the Mycobacterium 
tuberculosis complex (MTBC) which are characterized by 99.9% similarity at the nucleotide 
level and near identical 16S rRNA sequences (Parsons, Drewe et al. 2013, Alexander, Laver 
et al. 2010). However, these members differ in terms of host specificity, phenotype and 
pathogenicity (Brosch, Gordon et al. 2002). The MTBC includes M. tuberculosis,                
M. africanum, M. microti and M. bovis and newly recognized members include M. caprae, 
M. pinnipedii and M. canettii and M. origys (Huard, Fabre et al. 2006, Gey van Pittius, van 
Helden et al. 2012). Rare MTBC variants, the so-called dassie bacillus, M. mungi, and a 
newly identified member isolated from meerkats (Suricata suricatta) (Parsons, Drewe et al. 
2013) have been described (Alexander, Laver et al. 2010). The origin and evolution of the 
MTBC have intrigued researchers since their discovery. It is assumed that the MTBC 
members are derived from a common ancestor, but interestingly some members, for example 
M. tuberculosis, M. africanum and M. canettii, are exclusively found in humans whilst other 
members, like M. bovis, are seen as promiscuous, infecting a wide range of hosts (Brosch, 
Gordon et al. 2002). Other members are described as being host-specific, including              
M. caprae, M. origys and M. mungi which cause disease in goats, Arabian oryxes and banded 
mongoose, respectively (Huard, Fabre et al. 2006).  




Standard molecular tools used to delineate and speciate the MTBC include IS6110-
restriction fragment length polymorphism (RFLP) analysis, spacer oligonucleotide typing 
(Spoligotyping), MIRU-VNTR typing and regions of difference (RD) analysis. RD analysis 
of the MTBC members can distinguish between so-called human pathogens and animal-
adapted pathogens (Brosch, Gordon et al. 2002). All species that are primarily animal-
adapted belong to a single lineage that can be distinguished by the deletion of the 
chromosomal RD9, which is intact in all M. tuberculosis strains (Smith, Hewinson et al. 
2009). These animal-adapted strains include M. mungi (mongoose bacillus), dassie bacillus, 
M. origys (Arabian oryx bacillus), M. microti (vole bacillus), M. pinnipedii (seal bacillus),   
M. caprae (goat bacillus) and M. bovis (Smith, Hewinson et al. 2009).  
Whilst the incidence and prevalence of M. bovis cases in humans is far lower than    
M. tuberculosis, this pathogen is problematic in various settings in animal and human 
populations in a number of countries. Infection of animals by members of the MTBC is 
gaining greater recognition because these infections contribute to the high TB burden 
(Skinner, Wedlock et al. 2001). One such member from the MTBC is M. caprae. M. caprae 
infected goat herds can constitute a reservoir of TB inducing mycobacteria in the field, 
posing a risk of infection to cattle and wildlife (Cvetnic, Katalinic-Jankovic et al. 2007, 
Rodriguez, Bezos et al. 2011). Interestingly, M. caprae and M .bovis share most of the RD 
deletions, except for RD4 which is uniquely deleted in M. bovis (Smith, Hewinson et al. 
2009)(Smith, Hewinson et al. 2009, Smith, Yatsunenko et al. 2013) The similarity between 
the genomes of these two members with differing disease phenotypes provides an opportunity 
to study and attempt to explain how M. bovis is able to infect a wide range of hosts, whereas 
M. caprae predominantly infects goats. However, genomic analysis of closely related species 
may not directly explain specific phenotypes, host preferences or pathogenicity.  




Recent advances in mass spectrometry allow the simultaneous analysis of thousands 
of proteins. This technique enables the investigation of the strain differences between MTBC 
members at the level of the proteome, to explore possible proteomic variation which 
contributes to phenotype, host preferences and pathogenicity. The relationship between single 
nucleotide polymorphisms and protein abundance is not known and thus the analyses of final 
gene products could inform us what pathways are being used to regulate virulence and 
pathogenesis during infection in the host.   
 
1.2 Problem statement 
M. tuberculosis and M. bovis are the primary causative agents of tuberculosis in 
humans and animals, respectively. These species form part of the M. tuberculosis complex 
which shares 99.9% similarity at nucleotide level as well as near identical 16S rRNA 
sequences. Extensive genetic resources have not been able to clarify the mechanisms of 
pathogenicity between these members. We propose that analysing the proteins expressed in 
selected members of the M. tuberculosis complex the human-adapted M. tuberculosis H37Rv, 
the promiscuous animal-adapted M. bovis and the host-specific animal–adapted M. caprae; 
will enhance our understanding of what influences host-specificity in these members, as well 










1.3 Aims of study 
1. To characterize the proteomes of selected members of the MTBC, namely          
M. tuberculosis H37Rv, M. bovis and M. caprae. 
 
2. To compare abundances of proteins identified in M. bovis and M. caprae, relative 
to M. tuberculosis H37Rv.  
 
3. To identify proteins which may be involved in host-specificity and virulence 
mechanisms in M. bovis and M. caprae. 
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The genus Mycobacterium consists of over 120 known species, some of which (e.g. 
M. bovis and M. tuberculosis) contribute extensively to the burden of infectious disease in 
humans and animals, whilst others are commonly found in the environment but may rarely if 
ever be disease-causing. This paper reviews the Mycobacteria found in Southern Africa, 
focussing on those in the M. tuberculosis complex as well as the non-tuberculous 
Mycobacteria (NTMs) identifying those found in the area and including those causing disease 
in humans and animals, and outlines some recent reports describing the distribution and 
prevalence of the disease in Africa. Difficulties in diagnosis, host preference and reaction, 
immunology and transmission are discussed. 
2.2 Introduction 
Tuberculosis (TB) commonly occurs in humans and animals throughout the world, 
with Africa and particularly South Africa being a very high burden region with the incidence 
of M. tuberculosis in humans averaging 913/100 000 per annum (World Health 
Organization). Detailed and thorough prevalence surveys are rarely done, but the few that 
have been done show that infection with M. tuberculosis, the causative agent for TB in 
humans, is far more common than estimated from passive case finding (den Boon, van Lill et 
al. 2007). South Africa currently has the highest global burden of human disease from          
M. tuberculosis. It is not the purpose of this manuscript to reiterate that situation, other than 
to remark that the situation is complex, given that we know that the genus Mycobacterium, to 
which M. tuberculosis belongs, consists of a larger group of species, most of which have been 
shown to be able to cause different forms of Mycobacterial disease under the appropriate 
conditions (Petrini 2006, Moore, Kruijshaar et al. 2010, Phillips, von Reyn 2001, Simons, 
van Ingen et al. 2011, Warren, Gey van Pittius et al. 2006a). The fast growing species (less 
than 7 days in culture) are often non-pathogenic, whereas slow-growing species (more than 7 




days in culture) are mostly pathogenic (see Figure 2.1). The slow growing species include the 
members of the M. tuberculosis complex. Other species outside the complex are known as the 
non-tuberculous Mycobacteria (NTMs). Prevalence surveys, where Mycobacterial speciation 
has been done, have shown that non-tuberculous Mycobacteria (NTMs) may be up to three 
times more commonly found in humans than M. tuberculosis (Muyoyeta, de Haas et al. 2010) 
and own unpublished data). Similarly, although M. bovis is the most common cause of 
tuberculosis in animals, it cannot always be assumed to be the causative agent of tuberculosis 
in animals. 
The genus Mycobacterium currently consists of around 128 validly-published species 
and 5 subspecies with at least a further 34 species not fully described or named (van Helden, 
Parsons et al. 2009). They are commonly encountered in the environment, where niches 
include water, soil, protozoans, domestic and wild animals, invertebrates, and milk and food 
products (Falkinham 2010, Holland 2001, Michel, de Klerk et al. 2007). Some are obligate or 
opportunistic pathogens, but many are saprophytes. Apart from the common and well-known 
pathogenic Mycobacteria that are primarily transmitted between hosts, the environment can 
be a source of exposure to Mycobacteria. We have investigated water as a source for such 
and found M. terrae, M. vaccae (or vanbaalenii), M. engbaekii and M. thermoresistibile 
(Michel, de Klerk et al. 2007). Although not extensively investigated, there is clearly regional 
variation in the occurrence of Mycobacterial species e.g. M. ulcerans has not (yet) been 
found in southern Africa. However, with the movement of animals (and birds) often 
uncontrolled, one can expect the unexpected (e.g. the occurrence of M. origys in South Africa 
(Gey van Pittius, Perrett et al. 2012).  





Figure 2.1: The genus Mycobacterium. Well-known pathogens are mostly slow-growers. The 
species marked with a  ⃰  are NTMs isolated in South Africa from animals. Figure adapted from (Gey 








2.3 Mycobacterium tuberculosis complex members 
Mycobacteria grouped in the Mycobacterium tuberculosis complex (MTBC) are 
characterized by what is regarded as more than 99% similarity at the nucleotide level and 
near identical 16S rRNA sequences. The traditional members of the M. tuberculosis complex 
include the following four species: M. tuberculosis, M. africanum, M. microti and M. bovis. 
Newly recognized additions to the MTBC include M. caprae, M. pinnipedii and M. canettii, 
as well as potentially rarer or perhaps more geographically restricted MTBC variants, such as 
the so-called dassie (Parsons, Smith et al. 2008) and oryx bacillus, now known as M. origys, 
(Gey van Pittius, van Helden et al. 2012, van Ingen, Rahim et al. 2012) as well as M. mungi, 
which causes TB in the banded mongoose (Alexander, Laver et al. 2010). 
Infection of animals or humans by the members of the MTBC, most particularly      
M. tuberculosis and M. bovis, is clearly of concern, since these are the commonly recognised 
causes of the massive global burden of TB. Standard molecular tools used to delineate and 
speciate the MTBC are IS6110-restriction fragment length polymorphism (RFLP) analysis; 
spacer oligonucleotide typing (Spoligotyping); Regions of difference (RD) analysis and 
MIRU-VNTR typing. These tools can be used to position the different members of the 
MTBC into the phylogenetic tree of the complex (Figure 2.2).  
Our work shows that by far the majority of human tuberculosis cases (from              
M. tuberculosis) in South Africa originate from active and on-going transmission, and not 
reactivation disease and that this dynamic is valid for both antibiotic sensitive and resistant 
M. tuberculosis cases. (Hanekom, van der Spuy et al. 2007). Despite this enormous infection 
pressure, there have been very few cases of confirmed anthropozoonotic TB in South Africa 
specifically, viz. a single case of M. tuberculosis in a dog (Parsons, Gous et al. 2008) and     
M. tuberculosis in a zoo elephant (Michel, Venter et al. 2003, Tordiffe A et al., unpublished). 




However, a number of M. tuberculosis cases in livestock have been reported in Ethiopia and 
other African countries (Gumi, Schelling et al. 2012). 
 
Figure 2.2: The phylogeny of the Mycobacterium tuberculosis complex (MTBC) members based 
on genome differences, which can form the basis of differential diagnostics. Figure adapted from 
(Gey van Pittius, Perrett et al. 2012). 
 




Whilst the incidence and prevalence of M. bovis cases in humans is far lower than    
M. tuberculosis, this pathogen is problematic in various settings in animal and human 
populations in the different countries. However, in southern African countries (here defined 
as South Africa, Namibia, Zimbabwe, Zambia, Tanzania, and Mozambique) there are some 
considerable differences. In South Africa, almost all M. bovis occurs in the wildlife 
population, due to good disease control practice in the past, but historical invasion into the 
African buffalo (Michel, de Klerk et al. 2007, Michel, Coetzee et al. 2009). Whilst it has 
spread into at least 12 mammal species, it occurs predominantly in the wildlife parks and 
there is as yet no evidence to suggest spread across the interface into humans or domestic 
livestock (Michel, Muller et al. 2010). There are sporadic occurrences of M. bovis in 
domestic herds, but these are apparently well-controlled by state veterinarians. Zimbabwe 
claimed to have no M. bovis (in the past), whereas Zambia, Mozambique and Tanzania do. In 
Zambia, M. bovis commonly occurs in wildlife in Kafue (specifically lechwe) (Munyeme, 
Rigouts et al. 2009). In Mozambique, M. bovis is found in a number of provinces in 
livestock, even up to a prevalence of 60% based on skin testing in some districts (A. 
Machado, personal communication). In Tanzania, there is evidence for M. bovis in wildlife 
and domestic stock (up to 13% positivity) and a few cases of zoonotic M. bovis in humans 
have been reported (Katale, Mbugi et al. 2012). Since none of these countries can claim a full 
diagnostic service with speciation, the true picture with respect to zoonotic TB is unknown.  
The social behaviour in captive and free-living animal herds in African wildlife parks 
provide favourable conditions for M. bovis transmission to members of the same herd, for 
example buffalo in South Africa (Michel, de Klerk et al. 2007, Michel, Coetzee et al. 2009) 
and lechwe in Zambia (Munyeme, Rigouts et al. 2009). Transmission of the Mycobacterium 
tuberculosis complex members is also effective in species that maintain social or familial 
groups in underground dens. Drewe et al. conducted a study in a South African meerkat 




population and found that grooming (both giving and receiving) was more likely than 
aggression to be correlated with Mycobacterial disease transmission and that groomers were 
at higher risk of infection than groomees (Drewe, Eames et al. 2011).  
Although respiratory transmission is probably the most important route of infection in 
groups of animals that remain in close contact, indirect transmission via food is another 
important route (Kaneene, Thoen 2004). For oral transmission to occur, an uninfected animal 
has to consume feed or water contaminated with mucous or nasal secretions, faeces, or urine 
that contain the infective organisms or receive milk from an infected dam; therefore, the 
mycobacterium must be able to survive outside an infected host for sufficient time to be 
ingested by another animal. Research conducted in South Africa and elsewhere suggests that 
infected buffalo serve as a source of direct oral infection to large predators such as lions and 
scavenging omnivores such as warthogs (Michel, de Klerk et al. 2007, Michel, Coetzee et al. 
2009). 
2.4 Non-tuberculous Mycobacteria  
Most of the species included in the genus Mycobacterium are distinguished from the 
M. tuberculosis complex members by the fact that they are not obligate pathogens, but are 
inhabitants of the environment. Although these Mycobacteria are classified as saprophytes 
and live freely in the environment, they can be opportunistic pathogens, particularly in 
immunocompromised individuals. This latter factor is of major concern in high HIV 
prevalence settings, such as those found in many parts of Africa. For such individuals, there 
may be no such thing as a ‘non-pathogenic’ Mycobacterium.  
Unlike tuberculosis caused by M. tuberculosis, which is spread from human-human or 
human-animal or vice versa, non-tuberculous Mycobacterial infections have not been 
considered to be particularly contagious (Brown 1985). There is little or no evidence that the 




infection can be transmitted from one person to another. Several reports have debated the 
possibility of co-infection with both M. tuberculosis and NTM in individuals (Shamaei, 
Marjani et al. 2010). The role of NTMs, particularly when public health issues are concerned, 
should nevertheless not be ignored despite the fact that no definitive route of transmission is 
yet proposed. NTM and the pathologies they cause have received increasing attention world-
wide during the past decade (Griffith, Aksamit et al. 2007), despite the fact that the reported 
cases are still relatively few in numbers. Therefore, any disease episode, especially those 
presenting with clinical manifestations during their involvement merits being reported, along 
with the major Mycobacterial pathogens, such as M. tuberculosis, M. leprae, M. avium and 
M. bovis (Griffith, Aksamit et al. 2007). 
About one third of the NTMs has thus far been associated with disease in humans and 
can cause localized disease in the lungs, lymph glands, skin, wounds or bone (Katoch 2004). 
From a human and clinical perspective, amongst the most important slow-growing species 
are M. avium and M. intracellulare [the M. avium complex (MAC)].  
A recent clinical study in humans (Simons, van Ingen et al. 2011) based on data from 
a number of geographically distant regions in Asia showed that the M. avium complex was 
responsible for 56% of clinically relevant pulmonary disease (range 40-81%), M. abscessus 
for 35%, M. chelonae for 31%, M. kansasii and M. scrofulaceum for 17%, M. celatum 9%, 
M. szulgai 6%, M. fortuitum 5%, M. gordonae 2%, and M. terrae 1%. It is important to 
define what infection means, illustrated by the following example: in Denmark (Andrejak, 
Thomsen et al. 2010) 1,282 adult humans were diagnosed as NTM positive of which 26% 
had definite disease, 19% possible disease, and 55% colonization only. Five-year mortality 
after definite NTM disease was 40.1%. Infection with M. xenopi was found to be associated 
with worse prognosis than M. avium complex. Among 283 subjects studied in the USA (Yew, 
Sotgiu et al. 2011), 47% of them met ATS/IDSA (American Thoracic Society/ Infectious 




Diseases Society of America) pulmonary NTM disease criteria for a minimum overall 2-year 
period prevalence of 8.6/100,000 persons, and 20.4/100,000 in those at least 50 years of age. 
The prevalence ranged from 1.4 to 6.6 per 100,000. The prevalence of NTM lung disease 
globally appears to be increasing (Petrini 2006, Moore, Kruijshaar et al. 2010, Phillips, von 
Reyn 2001, Iseman, Marras 2008, Prevots, Shaw et al. 2010) by over 2.8% per year, mostly 
amongst persons older than 60 years of age, although in most parts of the world there is 
insufficient data to know how universal this may be. Thus, although the prevalence of disease 
from NTMs may be low, presence of NTM species is associated with a high likelihood of 
disease and thereafter mortality.  
From such detailed reports in human studies, one may reasonably assume that most if 
not all of these species could cause TB like disease in animal species and reports suggest that 
the M. avium complex (MAC, which includes M. intracellulare), M. kansasii, M. malmoense, 
M. xenopi, M. ulcerans, M. fortuitum, M. abscessus, and M. chelonae are indeed found in a 
significant number of animals such as cattle, deer, sheep, and goats, as well as wild and 
domesticated birds, fish, reptiles, and amphibians (Bercovier, Vincent 2001, Karne, Sangle et 
al. 2012). However, it is important to note that the presence of an NTM does not necessarily 
imply an active disease process.  
There are very few reports of NTMs isolated from animals, especially from Africa. 
This is partly because of the perception that NTMs rarely cause disease (with the exception of 
M. avium subsp paratuberculosis) and partly because identification and speciation of NTMs 
is relatively complex. However, Mycobacterial species (whether in the MTBC or NTMs) that 
have been identified to be disease-causing in African animals include M. goodii, M. origys, 
M. mungi, as well as a new species from the meerkat (Suricata suricatta), as yet undescribed 
(Parsons, Drewe et al. 2013) (in press). 




The following NTMs have been found to cause disease in Africa: M. avium is the 
most frequent bacterial opportunistic infection of AIDS (Karne, Sangle et al. 2012).            
M. fortuitum is most frequently isolated from fish and was found to produce a high mortality 
rate in South African fish farms (Bragg, Huchzermeyer et al. 1990); M. senegalense has been 
implicated in tuberculosis-like pathology of cattle in Africa (Bercovier, Vincent 2001). 
Whether a single agent is responsible for bovine farcy is still unclear, although Chamoiseau 
considered M. farcinogenes var. senegalense and M. farcinogenes var. tchadense to be the 
sole agents of bovine farcy because of the isolation of these species from the lesions 
(Chamoiseau 1973). M. kansasii has been detected in humans as well as in wild animals such 
as deer, camels, birds, monkeys and in water (which may be the natural reservoir) and was 
one of the first species shown to be responsible for non-tuberculous pulmonary infection 
(Bercovier, Vincent 2001). The impact of this important pathogen in human infection is 
regularly reported and is considerable; however it is a relatively rare pathogen of animals 
(Bercovier, Vincent 2001).  
Over the past few years, we have prepared various animal samples for Mycobacterial 
culture analysis when necropsy has been done as part of routine practice. Cultures obtained 
from bronchial washes, lymph nodes and lung material include the following species 
identified by 16S rRNA sequence analysis: M. abcessus, M. asiaticum, M. avium,                
M. brasilienses, M. chelonae, M. elephantis, M. engbackii, M. farcinogenes, M. fortuitum,     
M. gilven, M. gordonae, M. heraklionense, M. hiberniae, M. intracellulare, M. interjectum, 
M. lentiflavum, M. marseillense, M. moriokaense, M. nonchromogenicum, M. palustre,        
M. palveris, M. paraffinicum, M. phlei, M. senegalense, M. simiae, M. sherrisii, M. sphagni, 
M. terrae and M. vulneris.. Animal species examined were lions, rhinoceroses, banded 
mongooses, cattle, baboons, elephants and monkeys. The presence and isolation of these 
Mycobacteria does not imply active disease in each case. However, should any animal 




become immunocompromised, many species could be pathogenic. Thus, with rare 
exceptions, we have observed that Mycobacterial species other than M. tuberculosis, M. bovis 
and M. avium subsp paratuberculosis, seldom cause extensive disease, and very few reports 
exist in the literature. 
2.5 Geographical distribution and environmental determinants 
There is a reasonable body of literature regarding the distribution of the MTBC, but 
little concerning NTMs. These will both be discussed briefly below. Regional variations in 
the geographical distribution of Mycobacteria in Asia are reported and it is reasonable to 
expect a similar variation across Africa (Simons, van Ingen et al. 2011). Certainly, for 
example, this is supported by the localised occurrence of Mycobacterial species such as        
M. cannetti, M. ulcerans and subtypes of M. bovis. Specifically, M. ulcerans and M. bovis 
Af1 subtype are found predominantly in West Africa (Niemann, Richter et al. 2000),            
M. cannetti in the Horn of Africa (Pfyffer, Auckenthaler et al. 1998), M. bovis Af2 subtype in 
East Africa (Niemann, Richter et al. 2000), M. mungi in Botswana (Alexander, Laver et al. 
2010) and the Dassie bacillus and M. suricattae thus far in South Africa only (Parsons, 
Drewe et al. 2013, Parsons, Smith et al. 2008). Factors playing a role in distribution may 
include initial host range and topography, host specificity, and host susceptibility. 
Environmental factors leading to previously unrecorded species appearing sporadically in 
other regions, can be as a result of travel of animals, humans or birds, for example (De 
Groote, Huitt 2006)(Griffith, Aksamit et al. 2007). Alternatively, the apparent absence of a 
species from an area may simply be because no survey or relevant diagnostic work has been 
done there.  
With the exception of M. ulcerans, these are all members of the M. tuberculosis 
complex and this biodiversity suggests a possible origin for the M. tuberculosis complex to 
be “Out of Africa”, with regional evolution to explain the emergence of different strains or 




species of Mycobacteria. Further evidence to support this “Out of Africa” suggestion comes 
from work done in Ethiopia, where a new M. tuberculosis lineage has been found which is 
restricted to the Ethiopian highlands (Berg, Garcia-Pelayo et al. 2011).  
The distribution of NTMs may be regional or global: for example, the M. avium 
complex, M. abscessus, M. scrofulaceum, M. marinum and M. fortuitum are encountered 
globally, whilst M. malmoense is found mainly in Scandinavia (Griffith, Aksamit et al. 2007) 
and M. ulcerans mainly in Australia, Africa and South-East Asia (the tropics) (Ablordey, 
Swings et al. 2005). In Chad and Nigeria, the M. fortuitum complex was most frequently 
isolated from cattle and pigs (respectively) when they conducted a study to investigate 
tuberculosis (Bercovier, Vincent 2001). Similarly, pathogenic NTMs isolated from the 
pastoral ecosystems of Uganda included the M. avium complex (Muller, Steiner et al. 2008).  
Because of the presence of NTMs in the environment, human activities have had 
direct impacts on their ecology and hence their epidemiology (Kankya, Muwonge et al. 
2011), since humans have very substantially altered the living environment (Falkinham 
2010). This may provide new niches that some Mycobacteria can exploit and thereby increase 
our risk of exposure. An example of this is water supply systems, where Mycobacteria can 
easily form biofilms which are almost impossible to remove (Falkinham 2011). In all the 
habitats where NTMs have been recovered (Michel, de Klerk et al. 2007), the Mycobacteria 
are part of the normal flora, existing as stable, resident, and growing populations. An 
exception may be M. avium subsp. paratuberculosis, where growth and persistence in the 
environment has not been reported, despite being prevalent in bovidae worldwide. Farms or 
settlements with persistent infection have been described as sources of infection in this case 
(Whittington, Marsh et al. 2005) 




Compared to other bacteria, NTMs are relatively disinfectant-, heavy metal-, and 
antibiotic-resistant. Thus, the use of any antimicrobial agent selects for Mycobacteria. 
Employment of disinfectants for drinking water treatment leads to selection and enrichment 
of Mycobacteria in distribution systems in the absence of disinfectant-sensitive competing 
microorganisms (Falkinham 2010, Falkinham 2011). NTM selection may also occur as a 
consequence of the presence of antibiotics in drinking water and drinking water sources. 
Likewise, pollution, large scale agriculture, human and animal movement and a myriad of 
activities can provide microorganisms in general and Mycobacteria specifically with a rich 
opportunity to move and exploit their environment (Falkinham 2010, Falkinham 2011). 
Discovery that human behaviours lead to selection and proliferation of NTMs in 
habitats occupied by both humans and NTMs, creates the dilemma that human actions taken 
to reduce pathogen exposure (i.e., water disinfection), lead to possible increased NTM 
disease (Petrini 2006, Moore, Kruijshaar et al. 2010, Yew, Sotgiu et al. 2011, Prevots, Shaw 
et al. 2010).  
2.6 Hosts of Mycobacteria 
Some individuals (and species or strains of animals) are more susceptible to 
Mycobacterial disease than others. For example, in cattle it has been shown that various 
breeds have differing susceptibility to bovine TB (Ameni, Aseffa et al. 2007). Additionally, 
there is evidence to suggest that different populations of hosts may also select for certain 
pathogen types or subtypes (Hanekom, van der Spuy et al. 2007).  
Although it is largely M. tuberculosis that is found in active TB humans and M. bovis 
in terrestrial animals, Mycobacterium species can cross the species barrier in both the 
zoonotic and anthropozoonotic directions. Thus, cases of M. bovis in humans are well known, 
but less commonly, cases of M. tuberculosis have been reported in animals such as cats, dogs, 




and elephants (Parsons, Gous et al. 2008, LoBue, Enarson et al. 2010, Angkawanish, 
Wajjwalku et al. 2010), where the sources of these infections have commonly been traced to 
infected humans. However, there are many cases of M. tuberculosis in animal collections, 
where it is arguably an important cause of morbidity and mortality from infectious disease in 
captive wildlife (Montali, Mikota et al. 2001). Transmission of M. tuberculosis from animal 
to animal has not been conclusively shown, although extensive transmission is found with the 
animal-adapted species of the complex, such as M. bovis. Parsons et al. showed that            
M. tuberculosis antigens were found in 50% of dogs living in close contact with sputum 
smear-positive TB patients (Parsons, Warren et al. 2012). Since South Africa is rated as a 
high TB incidence and risk setting, it is not surprising that companion animals living in such 
environments will be exposed to this pathogen. Whether these animals can be reservoirs for 
human disease, in turn, is not known. Despite these cases of M. tuberculosis in animals, most 
free-living animals diagnosed as tuberculous are reported or regarded to be infected with      
M. bovis; therefore, infection with M. bovis is of public-health and economic importance.  
However, the complex members also cause TB; even if they show limited host or 
geographical association (see Table 2.1). For example, the recently described M. origys (Gey 
van Pittius, van Helden et al. 2012, van Ingen, Rahim et al. 2012) is apparently host-adapted 
to the antelope and found almost exclusively in the Arabian oryx (Oryx leucoryx) in the 
Middle East. However, the first isolation of this species in South Africa was from an African 
buffalo (Gey van Pittius, Perrett et al. 2012), however the history of this animal suggests that 
contact with Arabian oryxes was highly likely at some stage. This finding shows that infected 
animals with host-adapted pathogens which may at first appear to be host specific can 
sometimes infect a new host species.  
 




Table 2.1: M. tuberculosis complex species and their host-association 
Species Host (s) 
Found in Southern 
Africa 
M. tuberculosis Humans Yes 
M. canetti Humans No 
M. africanum Humans No 
M. mungi Banded mongoose Yes 
Dassie bacillus Dassies Yes 
M. origys Arabian oryxes Yes 
M. microti Voles, mice, shrews No 
M. pinnipedii Sea lions, fur seals No 
M. caprae Goats No 
M. bovis 
Bovids mainly, array of 
mammalian hosts 
Yes 
Note: this table is based on published data and is accurate as of June 2012 
 
2.7 Clinical signs and diagnoses 
Diagnoses of animals infected with M. tuberculosis or M. bovis are done using two 
primary immunological tests, namely the in vivo tuberculin skin test (TST) and the in vitro 
interferon-gamma (IFN-γ) release assay (IGRA). These tests typically rely on the detection of 
antigen-specific T lymphocyte-mediated responses as surrogate markers of infection by the 




causative organism. The IGRAs now include proteins largely specific to M. tuberculosis and 
M. bovis, such as early secretory antigenic target 6 kDa (ESAT-6) and culture filtrate protein 
10 kDa (CFP-10), for better diagnoses. These tests generally indicate infection and not active 
disease and are also not able to speciate (differentiate) the pathogen or definitively diagnose 
an infection or disease caused by an NTM. However, once a positive culture of NTMs has 
been obtained, the Capilia TB assay was found to be a quick and easy test to use for 
differentiation between the M. tuberculosis complex and NTM culture isolates (Muyoyeta, de 
Haas et al. 2010, Kaufmann 2002, de la Rua-Domenech, Goodchild et al. 2006).  
Because of the high incidence of M. bovis detected in a wide variety of animal species 
(and very high incidence of M. tuberculosis in humans) in Africa, it is not surprising that less 
emphasis is put on the diagnoses of NTM infection. This is the case in animals, even if the 
animal has tested positive for PPDAvium. It is particularly true in areas of high M. tuberculosis 
complex prevalence. In the face of a high disease burden from M. tuberculosis and M. bovis, 
many under-developed nations with inadequate health budgets, do not devote any attention to 
NTM infection, where the literature mostly reports an NTM incidence rate of less than 5/100 
000. However, recent studies in South and southern Africa show that one is likely to isolate 
NTMs from people suspected to have TB, at a rate at least equal to that with which               
M. tuberculosis is found. In fact, in some communities with a high prevalence of TB, far 
more NTMs than M. tuberculosis have been isolated from subjects (Muyoyeta, de Haas et al. 
2010, Chihota, Muller et al. 2012). From the disease and infection control perspective, it is 
important to know whether one is dealing with disease due to M. tuberculosis, complex or 
NTMs, since antibiotic susceptibility and control may differ. For example, in animal health 
work, the discovery of TB-like lesions in a livestock animal during necropsy and the easily 
derived but possibly incorrect diagnosis of M. bovis infection (Muller, de Klerk-Lorist et al. 
2011) may have devastating and unnecessary consequences for the herd owner.   




However, NTMs are increasingly identified due to better detection and speciation by 
PCR (Warren, Gey van Pittius et al. 2006a) or target-gene sequencing. Clinical signs of NTM 
disease manifestation vary depending on the extent and location of the lesions. NTM disease 
most commonly presents as pulmonary manifestations (Cook 2010). However, lymph node, 
skin, soft tissue involvement as well as disseminated disease are of clinical importance. 
Clinical presentation of pulmonary disease due to NTM may be similar to tuberculosis with 
the following clinical signs; low fever, night sweats, anaemia and weight loss, malaise, 
anorexia, diarrhoea and painful adenopathy in humans and in animals (Katoch 2004). Clinical 
diagnosis of tuberculosis is usually possible only after the disease has reached an advanced 
stage and is dependent on the site of lesions. At the time of diagnosis, most infected hosts 
may have shed bacilli and have been or are a potential source of infection for other hosts.  
Since it is relatively difficult to isolate, culture and speciate Mycobacteria, as well as 
decide whether the presence of that organism is simply colonization, or infection and disease, 
the literature on many of the complex species and for NTMs is not definitive. Isolation may 
simply represent recent acquisition, colonization without disease, or infection with disease 
implying clinical manifestation of tissue damage (at either micro or visible scale). 
Additionally, since NTMs are ubiquitous, great care must be exercised with sampling, since 
environmental contamination could occur (Hatherill, Hawkridge et al. 2006). It is clear that 
care must be taken in interpretation of diagnostic reports: if the only lab-based test used is a 
ZN (Ziehl-Neelsen) smear, then acid fastness may be over-interpreted as TB positive          
(M. tuberculosis or perhaps M. bovis) and dealt with appropriately, but incorrectly under the 
DOTS (directly observed therapy, short-course) programme. DOTS treatment of human 
pulmonary tuberculosis is started only on the basis of sputum microscopy results, which has 
an inherent possibility of misdiagnosing NTM disease, with subsequent incorrect treatment. 
For example, it has been noted that some of the cases that are identified as anti-TB treatment 




failure or suspected as drug resistance are actually due to NTMs (Griffith, Aksamit et al. 
2007). 
2.8 Conclusion 
Although the burden of disease from M. tuberculosis or M. bovis is apparently orders 
of magnitude higher than that from NTMs, NTMs can potentially carry a relatively high 
burden of morbidity and mortality since they may be difficult to diagnose and treat (van 
Ingen, Boeree et al. 2012). For the purposes of Mycobacterial disease control, care must be 
exercised where diagnosis is based only on macroscopic examination and perhaps smear or 
simple culture positivity, or immunological reactivity. We do not yet clearly understand the 
disease-causing potential of the various Mycobacteria in different animal species or the risk 
factors and drivers that may promote such disease, as opposed to exposure and infection. Our 
lack of such knowledge impacts on our ability to control these diseases and generate useful 
efficacious vaccines. The public health threat of tuberculosis in Africa requires urgent 
investigation on this topic through collaborative veterinary and medical research programs.  
























Reagents, solutions and media compositions are summarized in Appendix A. 
3.1 Bacterial strains 
The following species of the Mycobacterium tuberculosis complex were selected for 
proteomic analysis, namely M. tuberculosis H37Rv (ATCC 27294), Mycobacterium bovis 
(ATCC SB0267) and Mycobacterium caprae (ATCC BAA-824). 
3.2 Media and culture conditions 
Mycobacterial species were inoculated into Mycobacterial Growth Indicator Tubes 
(MGIT) (BD Biosciences, USA) and incubated at 37ºC until positive growth was detected 
using the Bactec 460 TB system (BD Biosciences, USA). Approximately 0.1 ml of the 
positive MGIT culture was plated out onto supplemented Middlebrook agar (BD Biosciences, 
USA) containing 0.2% (v/v) glycerol (Merck, USA), 0.05% (v/v) Tween® 80 (Sigma-
Aldrich, USA), and 10% (v/v) albumin-dextrose-catalase (0.5% BSA, 0.2% glucose, 0.015% 
catalase) (7H10ADC) and incubated at 37 ºC until single colony forming units (CFU’s) were 
visible.  
Stock cultures of each strain were made by inoculating single colonies into 7H9 
Middlebrook medium (BD Biosciences, USA) supplemented with 0.2% (v/v) glycerol, 0.1% 
(v/v) Tween® 80, and 10% (v/v) albumin-dextrose-catalase (7H9ADC) and incubated at 37ºC. 
Once the culture reached an A600 of 1.0, freezer stock cultures were made by mixing 300 μl of 
filter sterilized 50% glycerol with a 700 μl aliquot of Mycobacterial culture in 2 ml cryogenic 
tubes with O-rings and stored at -80ºC until further use.  
For proteomic analysis, freezer stock cultures were inoculated into 7H9ADC and 
incubated at 37ºC. 




Mycobacteria were cultured under strict biosafety level 3 (BSL3) conditions and all 
samples were decontaminated according to established protocols before removal from the 
BSL3 facility. 
3.3 Verification of Mycobacterial strains 
Mycobacterial cultures grown in 7H9ADC to A600 of 0.4 - 0.6 were tested for 
contamination using Ziehl-Neelsen staining and growth on blood agar plates. Boiled samples 
were prepared by boiling one ml of culture for one hour at 95ºC and used for spoligotyping, 
analysis of Regions of Difference PCR and IS6110 RFLP to confirm the identity of the 
Mycobacterial species.  
3.3.1 Ziehl-Neelsen staining 
Cultures of M. tuberculosis, M. bovis and M. caprae were screened for contamination 
using Ziehl-Neelsen staining (ZN staining) as described by Kent and Kubica (1985). Cultures 
were heat-fixed to microscope slides and flooded with ZN Carbol Fuchsin. The microscope 
slides were heated with a flame until steaming, followed by an incubation period of 5 minutes 
at room temperature. Slides were rinsed with water and decolourised with 5% acid-alcohol 
solution for 2 minutes, followed by a wash step with water. Slides were then counterstained 
using Methylene Blue for 1-2 minutes, rinsed with water and allowed to air dry. Slides were 
viewed with a light microscope under a 100X oil immersion lens. Uncontaminated cultures of 
M. tuberculosis, M. bovis and M. caprae appeared as pink acid fast bacilli, whereas 








3.3.2 Blood agar plates 
Cultures of M. tuberculosis, M. bovis and M. caprae were plated out on blood agar 
plates and incubated at 37ºC for 24 hours. No growth on the plates indicated no 
contamination of cultures.  
3.3.3 Spoligotyping  
Spoligotyping of each selected Mycobacterial species was done by Dr Elizabeth 
Streicher, according to the spoligotyping method previously described by Kamerbeek et al. 
1997 (Kamerbeek, Schouls et al. 1997), to genotypically identify each species. Each member 
of the M. tuberculosis complex has a specific spoligotyping signature (figure 3.1) (Streicher, 
Victor et al. 2007). 
 
 
Figure 3.2: Spoligotyping signatures of the Mycobacterium tuberculosis complex members. 









3.3.4 Regions of difference PCR 
Differentiation of the selected members of the MTBC was done by a two-step, 
multiplex PCR method based on the regions of difference (RD) in the Mycobacterial 
genomes (Warren, Gey van Pittius et al. 2006b). These regions include RD1, RD1mic, 
RD2seal, RD4, RD9 and RD12. Primers were designed according to Warren et al. 2006 (Table 
3.1) Each PCR reaction contained: 1 µl of DNA template, 2.5 µl of 10x buffer, 2 µl 25 mM 
MgCl2, 4 µl 10 mM dNTPs, 5 µl Q-buffer, 0.5 µl of each primer (50 pmol/µl), 0.125 µl 
HotStarTaq DNA polymerase (Qiagen, Germany) in a 25 µl reaction with (Warren, Gey van 
Pittius et al. 2006b). A negative control (no template) and a positive control (DNA template 
from M. tuberculosis H37Rv) were included to assay for contamination of the reagents and 
successful PCR amplification, respectively. Amplification was done by activating the Taq 
polymerase at 95ºC for 15 min, followed by 45 cycles of 94ºC for 1 min, 62ºC for 1 min and 
72ºC for 1 min., followed by a final elongation step at 72ºC for 10 min. The amplified 
products were fractionated on a 3.0% agarose gel in 1x TBE buffer, pH 8.3 at 6 V/cm for 4 












Table 3.1 PCR primer sequences for regions of deletion (RD) speciation of Mycobacterium 
tuberculosis complex members.  




  4 ATGTGCGAGCTGAGCGATC 
4 TGTACTATGCTGACCCATGCG 
4 AAAGGAGCACCATCGTCCAC 
  9 CAAGTTGCCGTTTCGAGCC 
9 CAATGTTTGTTGCGCTGC 
9 GCTACCCTCGACCAAGTGTT 
  12 GGGAGCCCAGCATTTACCTC 
12 GTGTTGCGGGAATTACTCGG 
12 AGCAGGAGCGGTTGGATATTC 
  1mic CGGTTCGTCGCTGTTCAAAC 
1mic CGCGTATCGGAGACGTATTTG 
1mic CAATCAGCCAAGACGAGGTTG 




3.3.5 IS6110 DNA fingerprinting 
Selected strains were genotyped using IS6110 DNA fingerprinting, by Ms Ruzayda 
van Aarde, according to internationally standardized methods (van Embden, Cave et al. 
1993). 
3.4 Growth curves of Mycobacterial strains 
Growth curves were done to determine the log phase for each selected Mycobacterial 
species. Mid-log phase was used for proteomic analyses to ensure that the species were under 
the most similar growth conditions and to limit changes in protein expression due to growth 
phase. Stock cultures of each strain were inoculated into 5 ml of 7H9 Middlebrook medium 




(BD Biosciences, USA) supplemented with 0.2% (v/v) glycerol, 0.1% Tween® 80, and 10% 
dextrose-catalase (7H9DC) and incubated at 37ºC. Once the starter culture reached an A600 of 
1.0, 1 ml of the culture was inoculated into 50 ml of 7H9DC. Absorbancy readings were taken 
every few days, the log phase growth curve plotted and mid-log Absorbances for                  
M. tuberculosis, M. bovis and M. caprae were calculated. 
3.5 Whole cell lysate protein extraction 
One ml freezer stock cultures of M. tuberculosis, M. bovis and M. caprae were 
inoculated into 10 ml of 7H9DC and incubated at 37ºC until an A600 of 0.6 - 0.7 was reached. 
One ml was re-inoculated into 50 ml of 7H9DC and incubated at 37ºC until the calculated 
mid-log phase for each selected strain was reached. Each Mycobacterial species was cultured 
in duplicate (biological replicates) and whole cell lysate proteins extracted in duplicate from 
each biological replicate (technical duplicates). 
Each culture was divided into two equal aliquots (25 ml) and the Mycobacterial cells 
were collected by centrifugation (10 min at 2500 x g) at 4ºC. The pellets were combined and 
re-suspended in 1 ml cold lysis buffer containing 10 mM Tris-HCl, pH 7.4 (Merck, 
Germany), 0.1% (v/v) Tween® 80, and 20 μl/ml protease inhibitor mixture (Protease 
Inhibitor set III, Merck, Germany). Re-suspended cells were transferred to 2 ml cryogenic 
tubes with O-rings and centrifuged (2x 1 min at 13 000 x g) at room temperature, with 1 min 
on ice between centrifugation steps. The supernatants were discarded and equal volumes of 
0.1 mm glass beads (Biospec Products Inc., OK) were added to the pelleted cells. 
Additionally, 300 μl of cold lysis buffer and 10 μl of 2 units/ml RNase-free DNase I (New 
England Biolabs) were added to each tube. The cells were lysed mechanically by bead 
beating for 20s in a Ribolyser (BIO101 Savant, Vista, CA) at the speed of 4.0 m.s-1.  




The respective tubes were cooled on ice for 1 min after ribolysing and this procedure 
was repeated six times. The lysates were centrifuged (2 min at 13 000 x g) at room 
temperature. Thereafter the tubes containing the separated lysate were immediately put on 
ice. Each supernatant (containing the whole cell lysate) was aspirated by passing through a 
0.22 μm millipore syringe sterile filter (Millipore Ireland Ltd., Carrigtwohill, CO. CORK 
IRL). The filtering step was repeated to ensure sterility. Each whole cell lysate was frozen 
overnight at -20ºC and stored at -80ºC. 
3.6 Protein concentration determination 
The Biorad RC-DC assay was used to determine the protein concentration of each 
whole cell lysate extraction according to the manufacturer’s instructions. A standard curve 
ranging from 0 mg/ml to 2 mg/ml was generated using the Quick StartTM Bovine Serum 
Albumin (BSA) Standard set (2 mg/ml). Protein absorbance was measured 
spectrophotometrically at 595 nm using the Ultrospec 4051(LKB Biochrom). The BSA 
absorbance readings were plotted as a standard curve and the whole cell lysate concentrations 
were determined from the curve.  
3.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
All reagents and buffers used for 1-D SDS-PAGE are described in Appendix A. 
Technical duplicates of each whole cell lysate biological replicate of M. tuberculosis H37Rv, 
M. bovis and M. caprae were separated on 4%- 12% gradient, 1.0 mm NuPage gels (Thermo 
Scientific, Germany) according to the manufacturer’s instructions.  
3.7.1 SDS-PAGE sample preparation 
A total of 60 µg of each whole cell lysate protein extract (technical duplicate) was 
added to 5 µl of 4x Laemmli sample buffer. The samples were mixed, pulse-centrifuged and 




boiled at 95ºC for 5 min to denature the proteins. Care was taken to not let samples cool 
down after denaturing. 
3.7.2 Electrophoresis and staining 
The gradient SDS-PAGE gels were placed in the running chamber and covered with 
0.2% XT MOPS running buffer (Biorad, USA). The combs were carefully removed and 6 µl 
of the pre-stained PageRulerTM protein ladder (Fermentas, Canada) was loaded as the 
molecular weight marker. Prepared whole cell lysate samples were loaded into the wells and 
separated at 150 Volts at 4 ºC.  
The gel was removed from the tank when the dye front reached the end of the gel and 
stained for 2 hrs with Imperial protein stain (Biorad, USA) on a shaker at room temperature. 
De-staining of the gel with milliQ (mQ) H2O took place overnight on a shaker at room 
temperature.  
3.8 Sample preparation for Mass Spectrometry (MS) analysis 
All reagents and buffers used for sample preparation of MS analysis are described in 
Appendix A. Technical duplicates of each biological replicate of each species were prepared 
for MS analysis. 
3.8.1 Peptide extraction 
Each gel lane, containing biological/technical replicates of whole cell lysate proteins, 
was fractionated into 10 fractions by excising the bands with a sterile scalpel on a sterile glass 
surface. For data analysis purposes, each gel lane was fractionated in the same way       
(Figure 3.2).  
 





Figure 3.8.1: Fractionation of gel lanes. Lane 2 and 3, and 5 and 6 represent technical duplicates of 
biological duplicates of whole cell lysates. Lane 1, 4 and 7 represent the pre-stained PageRulerTM 
protein ladder. NuPage 1.0mm, 4%-12% gradient were used with 0.2% XT MOPS running buffer. 
 
Each fraction was cut into smaller pieces of approximately 1 mm2 and transferred to a 
sterile micro-centrifuge tube. The gel pieces were washed by adding 300 µl of mQH2O and 
incubating for 10 min at room temperature. Thereafter the mQH2O was aspirated and the 
washing step was repeated. Subsequently, the gel pieces were de-stained by alternating wash 
steps with 300 µl 50% acetonitrile (ACN) and 50mM ammonium bicarbonate (ABC) for 10 
min each, until the gel pieces were decolourised. Gel pieces were dehydrated by adding 100% 
ACN for 10 min at room temperature. When the pieces had turned white, the ACN was 
aspirated and the gel pieces were dried in a speedy-vac for 20 min at room temperature. Gel 
pieces were rehydrated in 120 µl of 10 mM dithiothreitol (DTT) and incubated at 56 ºC for 
60 min to reduce any disulphide bonds. Thereafter the excess DTT was discarded by 
aspiration and the proteins were alkylated with the addition of 120 µl of 55 mM iodoacetic 
acid (IAA) followed by incubation in the dark at room temperature for 60 min. The excess 




IAA was then discarded and the gel pieces were washed with 300 µl of 50 mM ABC for 10 
min followed by a second wash with 300 µl of 50% ACN for 20 min. After aspirating the 
50% ACN, the proteins were in-gel digested with 80 µl of 10 ng/µl sequencing grade trypsin 
solution (Promega, USA) at 37⁰C for 17 hours. The reaction was stopped and peptides were 
eluted from the gel pieces with 70% ACN containing 0.1% formic acid. Hundred percent 
ACN was added to the gel pieces to elute the remaining peptides. 
3.8.2 Stage-tip activation 
Prior to mass spectrometry analysis, the peptide mixtures were cleaned and 
concentrated using self-made stop-and-go-extraction-tips (Stage-tips). Desalting columns 
were prepared by punching out discs of C18 empore filter (Merck, Germany) with a needle 
and ejecting the disks into sterile P200 pipette tips. The discs were securely wedged at the 
bottom of the tip. The supernatant containing the eluted peptides was dried in the speedy vac 
(Merck, Germany) to approximately 30 µl of sample. Samples were acidified by adding 20 µl 
of 5% formic acid. Stage-tips were activated by forcing 50  l of MeOH through the disk. The 
disk was washed with 50 µl of 5% formic acid. Acidified samples containing the peptides 
were run through the column twice, where after the disk was washed with 50 µl 5% formic 
acid. Peptides were eluted from the column with 50 µl of 80% ACN (with 5% formic acid) 












3.9 Mass spectrometry and data analysis 
Mass spectrometry work was done by Dr Salome Smit from the Central Analytical 
Facility, Stellenbosch University. All experiments were performed on a Thermo Scientific 
EASY-nLC II connected to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, 
Germany), equipped with a nano-electrospray source. 
Dried peptides were dissolved in 5% acetonitrile in 0.1% formic acid and 10 µl 
injections were made for nano-LC chromatography. For liquid chromatography, separation 
was performed on an EASY-Column (2 cm, ID 100µm, 5 µm, C18) pre-column followed by 
XBridge BEH130 NanoEase column (15 cm, ID 75 µm, 3.5 µm, C18) with a flow rate of 300 
nl/min. The gradient used was from 5-17% B in 5 min, 17-25% B in 90 min, 25-60% B in 10 
min, and 60-80% B in 5 min and kept at 80% B for 10 min. Solvent A was 100% water in 0.1 
% formic acid, and solvent B was 100 % acetonitrile in 0.1% formic acid.  
The mass spectrometer was operated in data-dependent mode to automatically switch 
between Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using the Xcaliber 
software package (Thermo Scientific, Germany). The precursor ion scan MS spectra (m/z 400 
– 2000) were acquired in the Orbitrap with resolution R = 60000 with the number of 
accumulated ions being 1 x 106. The 20 most intense ions were isolated and fragmented in 
linear ion trap (number of accumulated ions 1.5 x 104) using collision induced dissociation. 
The lock mass option (polydimethylcyclosiloxane; m/z 445.120025) enabled accurate mass 
measurement in both the MS and MS/MS modes. In data-dependent LC-MS/MS 
experiments, dynamic exclusion was used with 60 s exclusion duration. Mass spectrometry 
conditions were 1.8 kV, capillary temperature of 250°C, with no sheath and auxiliary gas 
flow. The ion selection threshold was 500 counts for MS/MS and an activation Q-value of 
0.25 and activation time of 10 ms were also applied for MS/MS.  




MaxQuant 1.2.2.5 was used to identify proteins via an automated database of all 
tandem mass spectra against the Uniprot solanum lycopersicum database (Cox, Mann 2008). 
A total of 80 RAW files which accounted for a total of 180 hours of acquisition time were 
submitted for protein identification using the TbDB M. tuberculosis H37Rv (GB:AL123456), 
TbDB M. bovis (AF2122/97) and an in-house custom database (de Souza, Arntzen et al. 
2011). Carbamidomethyl cysteine was set as fixed modification, and oxidized methionine, N-
terminal acetylation (protein), deamidation (NQ), pyro-Glu(Gln) and pyro-Glu(Glu) as 
variable modifications. The precursor mass tolerance was set to 20 ppm, and fragment mass 
tolerance set to 0.8 Da. Two missed tryptic cleavages were allowed. The following criteria 
were applied: peptide and protein false discovery rate of 1% (0.01), minimal peptide length of 
six, and a protein posterior error probability (PEP) of 0.01 and peptide PEP of 0.15. These 
extremely stringent parameters guarantee that proteins are identified with high confidence.  
Statistical analysis was done using Perseus. Data were transformed (log 2) and 
imputated (width 0.3, downshift 1.8) to replace missing values. Two samples ANOVA testing 
was performed using p-values with a threshold of 0.05. Proteins were only considered to be 
present if they were detected in all replicates that were done. Differential abundance was only 
considered if ≥ 2 fold abundance was observed ant the t-test value was p<0.05. For unique 
proteins, the proteins were present in all replicates of one species and absent in all replicates 











3.10 Bio-informatic analysis 
Each protein identified for M. tuberculosis, M. bovis and M. caprae was assigned to a 
functional category of proteins as defined by Cole et al. and summarised on the TubercuList 
knowledge base (Cole, Brosch et al. 1998). Pathway analysis for selected proteins was done 
using the Pathosystems Resource Integration Center (PATRIC) (Gillespie, Wattam et al. 
2011) and the Kyoto Encyclopedia of Genes and Genomes database (KEGG) (Kanehisa, 
Goto 2000). 
  























4.1 M. tuberculosis complex species verification 
Members of the Mycobacterium tuberculosis complex share 99.9% sequence identity 
at the nucleotide level and have near identical 16S rRNA sequences. Extensive verification 
steps were performed on the closely related bacteria studied here to ensure that proteomic 
analysis was done on the correct members. Mycobacterium caprae was cultured in 7H9 
media for the first time in our laboratory.  
Ziehl-Neelsen staining confirmed that cultures of M. tuberculosis H37Rv, 
Mycobacterium bovis (ATCC SB0267) and M. caprae (ATCC SB0416) contained only acid 
fast bacilli and were not contaminated. The absence of contamination was confirmed by the 
fact that no growth was detected after 48 hours on blood agar plates for all three cultures. 
Cultured M. tuberculosis H37Rv, M. bovis and M. caprae species were genotypically 
differentiated by spoligotyping, mapping of regions of difference (RD) PCR and IS6110 
RFLP fingerprinting. Figure 4.1.1 shows the spoligotyping signature for each member. The 
phylogenetic lineage representing M. bovis and M. caprae were characterized by an absence 
of direct variable repeats 39 to 43. M. caprae showed additional deletions of direct variable 
repeats 1, 3-4, 6-8, 28 and 30-33 when compared to M. bovis. 
 
 
Figure 4.1.1: Unique spoligotyping signatures of M. tuberculosis H37Rv, M. bovis and M. caprae. 
M. bovis BCG was used as the positive control in this experiment. 
 




Analysis of the regions of difference (RD) by PCR mapping (not shown) showed, as 
expected, that RD1, RD4, RD9 and RD12 were present in M. tuberculosis H37Rv. RD1 and 
RD4 were present in M. caprae while RD9 and RD12 were absent. RD1 was present in        
M. bovis while RD4, RD9 and RD12 were absent. These results correlate with previously 
published RD defined genomic comparisons. 
IS6110 DNA fingerprinting of M. bovis and M. caprae identified 1 and 6 copies of the 
IS6110 sequence, respectively (Figure 4.1.2). This differs from M. tuberculosis H37Rv which 
contains 16 copies of this insertion element (Cole, Brosch et al. 1998).  
 
Figure 4.1.2: IS6110 RFLP results for M. bovis and M. caprae. Lane 1, 2 and 3 show the RFLP 
results for M. bovis, M. caprae and the M. tuberculosis reference strain, respectively. 
 




4.2 Proteomic analysis of M. tuberculosis H37Rv, M. bovis and  M. caprae 
4.2.1 Whole cell lysate proteomic analysis 
Datasets of proteins identified in this study can be found in Appendix B (disk 
included), unless otherwise stated. Whole cell lysate protein extracts were harvested from 
mid-log phase cultures of M. tuberculosis H37Rv (A600 = 0.7), M. bovis (A600 = 0.65) and M. 
caprae (A600 = 0.7). Proteins were fractionated by SDS-PAGE (Figure 4.2.1.1) and in gel 
reduction/alkylation and trypsin digests were done. Proteins were identified using LC-
MS/MS on the Orbitrap Velos mass spectrometer. 
Figure 4.2.1.1: SDS-PAGE results for (a) M. tuberculosis H37Rv, (b) M. bovis and (c) M. caprae. 
Lanes 1, 5 and 9 in (a) and (c) and lanes 1, 4 and 7 in (b) represent the pre-stained PageRulerTM 
protein ladder. Whole cell lysate protein samples are represented by lanes 2-4 and 6-8 in (a) and (c) 
and lanes 2-3 and 5-6 in (b). NuPage 1.0mm, 4%-12% gradient were used with 0.2% XT MOPS 
running buffer. 
 
Functional groups were assigned using the 10 functional categories described by 
TubercuList, namely: cell wall and cell wall processes, information pathways, regulatory, 
intermediary metabolism and respiration, lipid metabolism, virulence, detoxification and 
adaptation, insertion sequences and phages, PE/PPE families; conserved hypothetical and 
hypothetical proteins.  
 




M. tuberculosis H37Rv 
A total of 13281 M. tuberculosis H37Rv peptides were identified by mass 
spectrometry, which corresponded to 2199 uniquely detected proteins based on these proteins 
being identified in both the biological and technical replicates. Seventy percent of the 
proteins detected were classified as intermediary metabolism and respiration, conserved 
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Mass spectrometry identified 16288 peptides which correlated to 2367 uniquely 
detected proteins. The detected proteins showed a similar distribution to M. tuberculosis 
H37Rv and the majority were assigned to three categories: intermediary metabolism and 
respiration, conserved hypotheticals and cell wall and cell wall processes (Figure 4.2.1.3).  
 
Figure 4.2.1.3: Whole cell lysate proteins of M. bovis grouped in functional categories. 
 
M. caprae 
Using the annotated genomes of M. tuberculosis H37Rv and M. bovis (the genome of 
M. caprae has not yet been sequenced or annotated), we identified a total of 14070 peptides 
using mass spectrometry that correlated with 2350 uniquely detected proteins. The 
Information 
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distribution of proteins in their respective functional categories was similar to that of            
M. tuberculosis H37Rv and M. bovis (Figure 4.2.1.4). 
 
Figure 4.2.1.4: Whole cell lysate proteins of M. caprae grouped in functional categories. 
 
Comparison of proteins which differentiate between M. tuberculosis H37Rv, M. bovis and 
M. caprae 
The whole cell lysate proteins detected in M. tuberculosis H37Rv, M. bovis and        
M. caprae were analysed to determine which proteins were uniquely detected in each species. 
A total of 1804 proteins were detected in all three strains, while 162, 131 and 183 proteins 
were uniquely detected in M. bovis, M. caprae and M. tuberculosis H37Rv, respectively 
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Figure 4.2.1.5: A Venn diagram showing the number of proteins detected in each of the three 
species, differentiating those that are common or unique amongst the three species. 
 
The uniquely detected proteins for each of the members were divided into functional 
groups (Figure 4.2.1.6). The distribution of the proteins in each species follows the same 
distribution pattern as the full constituent of detected proteins, with the largest numbers of 
unique proteins classified as intermediary metabolism and respiration, cell wall and cell wall 
processes and conserved hypotheticals. M. tuberculosis H37Rv had more than twice the 
number of uniquely detected proteins identified in the functional categories lipid metabolism 
and insertion sequences and phages, in comparison with M. bovis and M. caprae.  





Figure 4.2.1.6: Distribution of uniquely detected proteins in M. tuberculosis H37Rv (green), M. 
bovis (blue) and M. caprae (orange).  
 
M. bovis and M. caprae shared 284 proteins, which differentiate them from               
M. tuberculosis H37Rv. The 284 shared proteins between M. bovis and M. caprae were 
divided into functional groups (Figure 4.2.1.7). The distribution of the proteins follows the 
same distribution pattern as the uniquely detected proteins in each species, with the largest 
numbers of shared proteins classified as intermediary metabolism and respiration, cell wall 
and cell wall processes and conserved hypotheticals. 
Proteins which were unique to M. tuberculosis, M. bovis or M. caprae and proteins 
shared between two species only were included in the protein abundance datasets for 



































































Figure 4.2.1.7: Distribution of shared proteins between M. bovis and M. caprae.  
 
4.2.2 Analysis of the abundance of whole cell lysate proteins 
For analysis of protein abundance, the protein dataset of M. tuberculosis H37Rv was 
used as the reference for protein expression to which the abundance of proteins identified in 
M. bovis and M. caprae were compared. A two fold difference in protein abundance with a p-
value of <0.05 was considered significant. Only proteins detected in all four replicates of 
each species were used for further analysis.  
M. bovis 
We identified that 409 proteins were more highly abundant and 211 proteins were in 
lower abundance in M. bovis relative to M. tuberculosis H37Rv. Figure 4.2.2.1 shows the 
number of proteins from each functional group which were detected in greater or lesser 
abundance than in M. tuberculosis H37Rv. Functional groups intermediary metabolism and 





































of over-abundant proteins relative to M. tuberculosis H37Rv. The highest numbers of low 
abundance proteins were found in the following categories: conserved hypotheticals, 
intermediary metabolism and respiration and lipid metabolism.  
 
Figure 4.2.2.1: Functional groups of proteins detected in higher and lower abundance in           
M. bovis, relative to M. tuberculosis H37Rv. No significant differences were detected for functional 
groups Insertion sequences and phages, PE/PPE families and Hypothetical proteins in M. bovis, 
relative to M. tuberculosis H37Rv. 
 
M. caprae 
A total of 393 proteins were over-abundant by more than 2 fold and a total of 175 
proteins were under-abundant by more than 2 fold, in M. caprae relative to M. tuberculosis. 
Functional categories were assigned to the differentially expressed proteins (Figure 4.2.5) and 









































intermediary metabolism and respiration, cell wall and cell processes, conserved 
hypotheticals and lipid metabolism.  
 
 
Figure 4.2.2.2: Functional groups of proteins detected in higher and lower abundance in           
M. caprae, relative to M. tuberculosis H37Rv. No significant differences were detected for 
functional groups PE/PPE families and Hypothetical proteins in M. caprae. 
 
Comparison of differentially proteins detected in M. bovis and M. caprae    
Proteins which were over- and under-abundant in M. bovis and M. caprae were 
compared. A total of 222 over-abundant proteins were shared between these two species and 
187 and 172 proteins were uniquely over-abundant in M. bovis and M. caprae, respectively 
(Figure 4.2.2.3.a). Under-abundant proteins were distributed as 201 shared proteins, and 112 











































abundant and 201 under-abundant proteins in both M. bovis and M. caprae, had 
approximately the same fold difference in abundance, relative to M. tuberculosis H37Rv.  
 
 
Figure 4.2.2.3: Venn diagrams showing the number of proteins which were detected in (a) 
higher abundance or (b) lower abundance in M. bovis and M. caprae relative to M. tuberculosis, 
indicating the number which showed similar expression profiles in both strains relative to        
M. tuberculosis. 
 
Over- or under-abundant proteins detected only in one species were divided into 
functional groups (Figure 4.2.2.4). Functional groups that differed between these two species 
were information pathways, cell wall and cell processes and virulence, detoxification and 
adaptation. M. bovis had 25 higher abundant proteins in information pathways compared to 7 
in M. caprae. Thirteen less abundant proteins were indentified in cell wall and cell processes 
in M. bovis compared to 3 proteins in M. caprae. A total of 12 proteins were lower in 
abundance in M. bovis relative to M. caprae in virulence, detoxification and adaptation. 
Proteins detected in these over- and under abundant functional categories are summarized in 
Table 4.2.2.1. 
 




Figure 4.2.2.4: Functional categories of over-or under-abundant proteins detected only in        
M. bovis or M. caprae. Proteins detected in M. caprae in lower abundance (light orange) and higher 
abundance (dark orange). For M. bovis, the proteins are shown in light and dark blue for lower and 
higher abundant proteins, respectively. No proteins were only found in the PE/PPE families, as well 
as the Insertion sequences and phages category for M. bovis. 
 
  




Table 4.2.2.1: Summary of higher and lower-abundance proteins detected in only one species in 










Rv0003 Information pathways 3.0 recF DNA recombination and repair protein RecF
Rv0640 Information pathways 2.9 rplK LSU ribosomal protein L11p (L12e)
Rv0682 Information pathways 2.3 rpsL SSU ribosomal protein S12p (S23e)
Rv0700 Information pathways 2.4 rpsJ SSU ribosomal protein S10p (S20e)
Rv0701 Information pathways 3.6 rplC LSU ribosomal protein L3p (L3e)
Rv0704 Information pathways 2.9 rplB LSU ribosomal protein L2p (L8e)
Rv0705 Information pathways 3.4 rpsS SSU ribosomal protein S19p (S15e)
Rv0706 Information pathways 3.5 rplV LSU ribosomal protein L22p (L17e)
Rv0709 Information pathways 3.9 rpmC LSU ribosomal protein L29p (L35e)
Rv0714 Information pathways 2.6 rplN LSU ribosomal protein L14p (L23e)
Rv0715 Information pathways 4.2 rplX LSU ribosomal protein L24p (L26e)
Rv0720 Information pathways 4.1 rplR LSU ribosomal protein L18p (L5e)
Rv0722 Information pathways 6.6 rpmD LSU ribosomal protein L30p (L7e)
Rv0979A Information pathways 2.3 rpmF LSU ribosomal protein L32p
Rv1643 Information pathways 2.3 rplT LSU ribosomal protein L20p
Rv2228c Information pathways 2.0 Rv2228c FIG006762: Phosphoglycerate mutase family
Rv2357c Information pathways 2.0 glyS Glycyl-tRNA synthetase (EC 6.1.1.14)
Rv2412 Information pathways 2.9 rpsT SSU ribosomal protein S20p
Rv2441c Information pathways 5.8 rpmA LSU ribosomal protein L27p
Rv2442c Information pathways 4.4 rplU LSU ribosomal protein L21p
Rv2534c Information pathways 2.7 efp Translation elongation factor P
Rv2985 Information pathways 4.8 mutT1 Possible hydrolase mutT1 
Rv2986c Information pathways 2.5 hupB DNA-binding protein HU / low-complexity
Rv3456c Information pathways 3.5 rplQ LSU ribosomal protein L17p
Rv3580c Information pathways 2.6 cysS Cysteinyl-tRNA synthetase 
Rv0949 Information pathways 2.0 uvrD1 Probable ATP-dependent DNA helicase II
Rv1108c Information pathways 2.6 xseA Exonuclease VII large subunit
Rv1640c Information pathways 2.7 lysX Possible lysyl-tRNA synthetase 2
Rv2528c Information pathways 4.7 mrr Probable restriction system protein 
Rv3296 Information pathways 2.1 lhr Probable ATP-dependent helicase LHR
Rv3597c Information pathways 2.0 lsr2 Iron regultaed H-NS-like protein
Rv3834c Information pathways 2.0 serS Seryl-tRNA synthetase 
Rv0290 Cell wall and cell processes 2.1 eccD3 Esx conserved component eccD3
Rv0394c Cell wall and cell processes 2.1 Rv0394c Possible secreted protein
Rv0411c Cell wall and cell processes 3.2 glnH Probable glutamine-binding lipoprotein
Rv0425c Cell wall and cell processes 3.6 ctpH Possible metal cation transporting P-type ATPase
Rv0482 Cell wall and cell processes 2.3 murB UDP-N-Acetylenolpyruvoylglucosamine reductase
Rv0638 Cell wall and cell processes 2.4 secE1 Probable preprotein translocase 
Rv0875c Cell wall and cell processes 3.0 Rv0875c Possible conserved exported protein
Rv2115c Cell wall and cell processes 2.2 mpa Mycobacterial proteasome ATPase
Rv3193c Cell wall and cell processes 4.5 Rv3193c Probable conserved transmembrane protein
Rv3809c Cell wall and cell processes 2.6 glf UDP-galactopyranose mutase 
Rv3865 Cell wall and cell processes 2.1 espF Esx-1 secretion associated protein 
Rv3919c Cell wall and cell processes 4.4 gid Probable glucose-inhibited division protein B
Rv3921c Cell wall and cell processes 6.5 Rv3921c Probable conserved transmembrane protein
Rv0251c Virulence, detoxification and adaptation 5.6 hsp Heat shock protein 
Rv0634c Virulence, detoxification and adaptation 4.3 Rv0634c Possible glyoxalase II
Rv1114 Virulence, detoxification and adaptation 4.6 vapC32 Possible toxin vapC32
Rv1608c Virulence, detoxification and adaptation 3.4 bcpB Probable peroxidoxin
Rv1901 Virulence, detoxification and adaptation 27.6 cinA Probable cinA-like protein
Rv1932 Virulence, detoxification and adaptation 4.8 tpx Probable thiol peroxidase
Rv1962c Virulence, detoxification and adaptation 2.1 vapC35 Possible toxin vapC35
Rv2416c Virulence, detoxification and adaptation 33.0 eis Enhanced intracellular survival protein 
Rv2428 Virulence, detoxification and adaptation 82.8 ahpC Alkyl hydroperoxide reductase C protein
Rv2494 Virulence, detoxification and adaptation 3.0 vapC38  Possoble toxin vapC38
Rv3100c Virulence, detoxification and adaptation 6.2 smpB Probable SSRA-binding protein
Rv3661 Virulence, detoxification and adaptation 2.6 Rv3661 Conserved hypothetical protein
Rv0934 Cell wall and cell processes 7.3 pstS1 Periplasmic phosphate-binding lipoprotein
Rv2150c Cell wall and cell processes 8.7 ftsZ Cell division protein




























































4.3 Pathway analysis of differentially abundant proteins detected in M. bovis and  
      M. caprae 
 
To provide an integrated overview of the overall network of protein expression (rather 
than just limit analysis to individual proteins), pathway analysis was done on the 
differentially expressed proteins of M. bovis and M. caprae. Proteins were assigned pathway 
categories in PATRIC (Pathosystems Resource Integration Center) and visualized using 
iTUBY (Interactive Pathway Explorer database). Pathways highlighted in the figures indicate 
altered protein abundance relative to M. tuberculosis H37Rv.  
M. bovis 
PATRIC analysis showed that most of the 409 higher abundant proteins in M. bovis 
contribute to/function in valine, leucine and isoleucine degradation, fatty acid metabolism 
and oxidative phosphorylation (Table 4.3.1). Pathway results correlated with the analysis and 
visualization of these proteins in iTUBY and also showed that Xenobiotic degradation and 
ribosomal protein pathways were influenced (Figure 4.3.1). The 187 over-abundant proteins 
that were only detected in M. bovis follow the same functional group and pathway 
distribution (data not shown). Analysis on PATRIC and iTUBY showed that the 211 lower 
abundant proteins, which include the 112 lower abundance proteins only detected in M. bovis, 








Table 4.3.1: Summary of pathways affected by the higher abundance proteins in M. bovis 
relative to M. tuberculosis. 
Pathway Name Number of proteins 
Valine, leucine and isoleucine degradation 18 
Fatty acid metabolism 17 
Oxidative phosphorylation 16 
Arginine and proline metabolism 15 
Butanoate metabolism 15 
Methane metabolism 14 
Tryptophan metabolism 14 
Phenylalanine metabolism 13 
Reductive carboxylate cycle (CO2 fixation) 12 
Propanoate metabolism 12 
 
 
Figure 4.3.1: Pathway analysis of higher abundance proteins of M. bovis compared to               
M. tuberculosis H37Rv. Lipid metabolism, amino acid metabolism, xenobiotic degradation, oxidative 
phosphorylation and ribosomal protein pathways are noticeably affected. Proteins that mapped to the 
pathways are illustrated in red. 
 




Table 4.3.2: Summary of pathways affected by the lower abundant proteins in M. bovis, relative 
to M. tuberculosis.  
Pathway Name Number of proteins 
Fatty acid metabolism 13 
Biotin metabolism 6 
Valine, leucine and isoleucine degradation 6 
Fatty acid biosynthesis 5 
alpha-Linolenic acid metabolism 5 
Pyrimidine metabolism 5 
Benzoate degradation via hydroxylation 5 
Phenylalanine, tyrosine and tryptophan biosynthesis 4 




Figure 4.3.2: Pathway analysis of lower abundance proteins of M. bovis compared to                 
M. tuberculosis H37Rv. The lipid metabolism pathway is highly affected. Proteins that mapped to the 
pathways are illustrated in red. 
 
 





Pathway analysis using the PATRIC database concluded that the 394 higher 
abundance proteins were mostly involved in oxidative phosphorylation, methane metabolism, 
valine, leucine and isoleucine degradation and glycolysis (Table 4.3.3). Analysis of these 
proteins using iTUBY showed that carbohydrate metabolism, lipid metabolism, amino acid 
metabolism, xenobiotic degradation and oxidative phosphorylation were affected (Figure 
4.3.3). Most of the 172 over-abundant proteins only detected in M. caprae where found in 
these pathways. The 175 down-regulated proteins, which include the 75 proteins only 
detected in M. caprae, were mostly found in the pyrimidine metabolism, purine metabolism 
and lipid metabolism pathways (Table 4.3.4 and Figure 4.3.4). 
 
Table 4.3.3: Summary of pathways affected in M. caprae using the higher abundant proteins, 
relative to M. tuberculosis. 
Pathway Name Number of Proteins 
Oxidative phosphorylation 18 
Methane metabolism 15 
Valine, leucine and isoleucine degradation 15 
Propanoate metabolism 13 
Glycolysis / Gluconeogenesis 12 
Fatty acid metabolism 12 
Pyruvate metabolism 11 
Nitrogen metabolism 10 
Reductive carboxylate cycle (CO2 fixation) 10 
Arginine and proline metabolism 10 
 





Figure 4.3.3: Pathway analysis of higher abundance proteins in M. caprae compared to             
M. tuberculosis H37Rv. Carbohydrate metabolism, lipid metabolism, amino acid metabolism, 
xenobiotic degradation and oxidative phosphorylation pathways were affected. Proteins that mapped 
to the pathways are illustrated in red. 
 
 
Table 4.3.4: Summary of pathways affected by the lower abundant proteins in M. caprae, 
relative to M. tuberculosis. 
Pathway Name Number of Proteins 
Purine metabolism 9 
Fatty acid metabolism 8 
Pyrimidine metabolism 6 
Lysine biosynthesis 4 
Glycerophospholipid metabolism 4 
Porphyrin and chlorophyll metabolism 4 
Citrate cycle (TCA cycle) 3 
Cysteine and methionine metabolism 3 
Amino sugar and nucleotide sugar metabolism 3 
Pyruvate metabolism 3 
 





Figure 4.3.4: Pathway analysis of lower abundance proteins of M. caprae compared to              
M. tuberculosis H37Rv. Lipid metabolism and pyrimidine metabolism pathways were highly 
affected. Proteins that mapped to the pathways are illustrated in red. 
 
4.4 RD deletions  
M. tuberculosis complex members can be distinguished based on RD deletions.          
M. bovis and M. caprae share RD5, RD7, RD8, RD9, RD12 and RD13, but can be 
distinguished based on RD4 which is absent in M. bovis. Proteins associated with the RD5, 
RD7, RD8, RD9, RD12 and RD13 deletion regions (Table 4.4) were not found in the protein 
datasets for M. bovis or M. caprae, confirming the deletion of these regions. Proteins 
associated with RD4 were found in M. caprae.  




Table 4.4: Regions of deletion and their associated proteins. M. bovis and M. caprae share the 





Protein Gene Functional category Proposed function of protein
Rv1505c Rv1505c Conserved hypotheticals Conserved hypothetical protein
Rv1507A Rv1507A Unknown Hypothetical protein
Rv1507c Rv1507c Conserved hypotheticals Conserved hypothetical protein
Rv1508c Rv1508c Cell wall and Cell processes Probable membrane protein
Rv1508A Rv1508A Conserved hypotheticals Conserved hypothetical protein
Rv1509 Rv1509 Unknown Hypothetical protein
Rv1510 Rv1510 Cell wall and Cell processes Conserved Probable membrane protein
Rv1511 gmdA Intermediary metabolism and respiration GDP-D-mannose dehydratase
Rv1512 epiA Intermediary metabolism and respiration Probable nucleotide-sugar epimerase
Rv1513 Rv1513 Conserved hypotheticals Conserved hypothetical protein
Rv1514c Rv1514c Conserved hypotheticals Conserved hypothetical protein
Rv1515c Rv1515c Conserved hypotheticals Conserved hypothetical protein
Rv1516c Rv1516c Intermediary metabolism and respiration Probable sugar transferase
Rv3117 cysA3 Intermediary metabolism and respiration Probable thiosulphate sulfurtransferase
Rv3118 sseC1 Intermediary metabolism and respiration Conserved hypothetical protein
Rv3119 moaE1 Intermediary metabolism and respiration Probable molybdenum cofactor biosynthesis protein
Rv3120 Rv3120 Conserved hypothetical Conserved hypothetical protein
Rv3121 cyp141 Intermediary metabolism and respiration Ptobable cytochrome P450
Rv1964 yrbE3A Virulence, detoxification, adaptation Conserved hypothetical integral membrane protein YRBE3A
Rv1965 yrbE3B Virulence, detoxification, adaptation Conserved hypothetical integral membrane protein YRBE3B
Rv1966 mce3A Virulence, detoxification, adaptation MCE-family protein MCE3A
Rv1967 mce3B Virulence, detoxification, adaptation MCE-family protein MCE3B
Rv1968 mce3C Virulence, detoxification, adaptation MCE-family protein MCE3C
Rv1969 mce3D Virulence, detoxification, adaptation MCE-family protein MCE3D
Rv1970 lprM Cell wall and Cell processes Possible MCE-family lipoprotein 
Rv1971 mce3F Virulence, detoxification, adaptation MCE-family protein MCE3F
Rv1972 Rv1972 Cell wall and Cell processes Probable conserved MCE associated membrane protein
Rv1973 Rv1973 Cell wall and Cell processes Possible conserved MCE associated membrane protein
Rv1974 Rv1974 Cell wall and Cell processes Probable conserved membrane protein
Rv1975 Rv1975 Conserved hypotheticals Conserved hypothetical protein
Rv1976c Rv1976c Conserved hypotheticals Conserved hypothetical protein
Rv1977 Rv1977 Conserved hypotheticals Conserved hypothetical protein
Rv3617 ephA Virulence, detoxification, adaptation Probable epoxide hydrolase
Rv3618 Rv3618 Intermediary metabolism and respiration Possible monooxygenase
Rv3619c esxV Cell wall and Cell processes Putative ESAT-6 like protein ESXV (ESAT-6 like protein 1)
Rv3620c esxW Cell wall and Cell processes Putative ESAT-6 like protein ESXW (ESAT-6 like protein 10)
Rv3621c PPE65 PE/PPE PPE family protein PPE65
Rv3622c PE32 PE/PPE PE family protein PE32
Rv3623 lpqG Cell wall and Cell processes Probable Conserved lipoprotein LPQG
Rv2072c cobL Intermediary metabolism and respiration Precorrin-6Y C(5,15)-methyltransferase
Rv2073c Rv2073c Intermediary metabolism and respiration Probable shortchain dehydrogenase
Rv2074 Rv2074 Intermediary metabolism and respiration Possible pyridoxamine 5'-phosphate oxidase
Rv2075c Rv2075c Cell wall and Cell processes Possible hypothetical exported or envelop protein
Rv0221 Rv0221 Lipid metabolism Possible triacylglycerol synthase
Rv0222 echA1 Lipid metabolism Probable enoyl-CoA hydratase
Rv0223c Rv0223c Intermediary metabolism and respiration Probable aldehyde dehydrogenase
Rv0866 moaE2 Intermediary metabolism and respiration Probable molybdenum cofactor biosynthesis
Rv3119 moaE1 Intermediary metabolism and respiration Probable molybdenum cofactor biosynthesis
Rv3120 Rv3120 Conserved hypotheticals Conserved hypothetical protein
Rv3121 cyp141 Intermediary metabolism and respiration Probable cytochrome P450
Rv1255c Rv1255c Regulatory proteins Probable transcriptional regulatory protein
Rv1256c cyp130 Intermediary metabolism and respiration Probable cytochrome P450

































In this study we aimed to characterize the proteomes of the closely related 
Mycobacterium tuberculosis complex members in relation to M. tuberculosis H37Rv,          
M. bovis and M. caprae. M. bovis and M. caprae are animal-adapted species and cause 
disease mainly in bovidae and goats, respectively. M. bovis is a promiscuous species and has 
also been isolated from an array of mammalian species such as humans, deer, llamas, pigs, 
domesticated animals and wildlife. The relative abundances of the proteins identified in the 
animal-adapted strains, M. bovis and M. caprae, were compared to M. tuberculosis H37Rv. 
The metabolic pathways influenced by the proteins which were uniquely detected in a 
defined member, or were differentially abundant, were analyzed to explore their possible 
roles in host-specificity and virulence mechanisms. 
Genomic analysis versus proteomic analysis 
The 4.4 Mb M. tuberculosis H37Rv genome and 4.3 Mb M. bovis AF2122/97 genome 
share >99.95% sequence identity (Garnier, Eiglmeier et al. 2003). Importantly, there are no 
unique genes in M. bovis, suggesting that differential gene expression and subsequent protein 
abundances, in conjunction with absence of the genes encoded in the RDs are important 
determinants in host-specificity and virulence (Garnier, Eiglmeier et al. 2003). M. caprae is 
closely to M. bovis although its genome has not been sequenced, and therefore it may be 
assumed that genome sequence of this member would show sequence identity with exception 
of unique polymorphisms and deletions  
Considering the similarity between genomes, it was no surprise that the functional 
distribution of the 2199, 2367 and 2350 detected proteins extracted during log-phase growth 
was similar for M. tuberculosis H37Rv, M. bovis and M. caprae respectively. Cole et al. 
identified 3924 predicted protein-encoding open reading frames in the M. tuberculosis 
H37Rv genome and later added another 82 when the genome was re-annotated (Cole, Brosch 
et al. 1998). This implies that 54.8%, 59.1% and 58.7% of the proposed M. tuberculosis 




proteins are expressed and detectable in M. tuberculosis H37Rv, M. bovis and M. caprae, 
respectively. 
M. bovis and M. caprae share the RD5, RD7, RD8, RD9, RD12 and RD13 deletions, 
but can be distinguished based on RD4 which is deleted only in M. bovis. However, most of 
the proteins encoded within RD4 are classified as conserved hypothetical proteins and 
thereby their functions remain unknown. Analysis of the functional group distribution of 
proteins detected and pathways affected by higher or lower abundant proteins in these two 
species, it was evident that the RD4 deletion does not play a major role in the differentiation 
of these members. RD5, RD7 and RD8 encode mammalian cell entry (MCE) proteins and 
ESAT-6 family proteins, which are part of the virulence mechanisms of M. tuberculosis 
H37Rv (Garnier, Eiglmeier et al. 2003). The consequence of the deletion of these genes and 
subsequent absence of these proteins in M. bovis and M. caprae are difficult to predict. 
Deletion of the MCE proteins could explain why M. bovis and M. caprae prefer specific 
hosts. ESAT-6 family proteins which have been deleted have been said to have an impact on 
the antigen load either singly or in combination (Sørensen, Nagai et al. 1995). It has been 
suggested that strong selective pressure, imposed by the host immune system, may have 











Metabolic pathway analysis of differentially abundant proteins 
Metabolic pathways affected by the proteins which were in higher abundance in        
M. bovis relative to M. tuberculosis H37Rv included amino acid metabolism, lipid 
metabolism, oxidative phosphorylation, ribosomal proteins and xenobiotic degradation. The 
over-abundant proteins in M. caprae were also involved in amino acid metabolism, lipid 
metabolism, oxidative phosphorylation and xenobiotic degradation, as well as carbohydrate 
metabolism. Lower abundance proteins in M. bovis and M. caprae, relative to M. tuberculosis 
H37Rv, were found in lipid metabolism and pyrimidine metabolism. The affected metabolic 
pathways and their possible involvement in host-specificity are discussed below. 
Amino acid metabolism 
Proteins involved in valine, leucine and isoleucine metabolism were over-abundant in 
M. bovis and M. caprae. Mycobacteria have the capacity to synthesize these branched-chain 
amino acids (Grandoni, Marta et al. 1998), and the over-abundance of these proteins may 
indicate increased synthesis of these amino acids in M. bovis and M. caprae relative to         
M. tuberculosis. Leucine auxotrophs of M. bovis BCG were found to have a reduced ability to 
survive in the spleens and lungs of mice (McAdam, Weisbrod et al. 1995), suggesting that 
leucine metabolism is required for virulence of M. bovis (Grandoni, Marta et al. 1998), and 
similarly in M. caprae. Mammalian hosts are unable to produce branched chain amino acids; 
therefore increased synthesis of these amino acids may be advantageous to these pathogens 
during infection. This could explain why M. bovis is able to infect a variety of hosts and 
seeing as the intermediates formed during valine, leucine and isoleucine metabolism and the 
enzymes responsible for these reactions could be targets for preventing pathogenesis of these 
species (Grandoni, Marta et al. 1998). Since mammals do not produce enzymes involved in 
branched-chain amino acid synthesis; these enzymes could be targeted for anti-tuberculosis 
drugs with little toxicity to the animal host (Grandoni, Marta et al. 1998).  




Lipid and fatty acid metabolism 
An estimated 8% of the genome of M. tuberculosis H37Rv is dedicated to the 
activities of lipid and fatty acid metabolism (Cole, Brosch et al. 1998). M. tuberculosis 
complex members are unique among bacterial pathogens in that they display complex lipids 
and lipoglycans on their cell surface (Converse, Mougous et al. 2003). Cell wall lipids are 
required for virulence because they interact with the host cell receptors leading to cell 
invasion (Brennan, Nikaido 1995), provide protection against host damage (Rousseau, Winter 
et al. 2004) and modulate the immune response to infection (Reed, Domenech et al. 2004). 
Several cell wall lipoproteins, trans-membrane proteins and cell wall transfer proteins were 
over-abundant in M. bovis and M. caprae relative to M. tuberculosis H37Rv. This could 
imply that M. bovis and M caprae have a unique cell wall composition which better suits 
them for survival in their specific hosts.  
M. bovis and M. caprae showed an increased abundance of lipid and fatty acid 
metabolism-related proteins, relative to M. tuberculosis H37Rv. Amongst the over-abundant 
proteins are several fatty acyl CoA synthases and dehydrogenases. It has been proposed that 
fatty acid CoA synthases and dehydrogenases together with polyketide synthases, which 
synthesize secondary metabolites such as antibiotics in other Actinomycetes, are involved in 
the synthesis of complex lipids (Kolattukudy, Fernandes et al. 1997). Experiments with 
mutant strains of M. tuberculosis have shown that a deficiency in complex lipid biosynthesis 
can lead to hypo-virulence of previously ‘hyper-lethal’ behavior in murine infection models 
(Reed, Domenech et al. 2004), reduced growth in the lungs of infected mice (Cox, Chen et al. 
1999) and reduced translocation of lipids to the outer cell membrane (Camacho, Constant et 
al. 2001). Thus, the up-regulation of this pathway could increase the virulence and disease 
manifestation potential of M. bovis and M. caprae in their respective hosts.  




M. tuberculosis complex members rely on the host cell for a carbon source for 
survival and therefor the ability to adapt to their immediate environment is important. During 
infection, M. tuberculosis uses fatty acids and cholesterol instead of carbohydrates as a main 
carbon source (Bloch, Segal 1956). However, in this study these species were cultured in 
7H9DC media, containing no primary source of fatty acids or cholesterol, which may imply 
that there was either an innate increase in the expression of these proteins, or that these 
strains are less equipped to use other carbon sources and are increasing the expression of 
these proteins in an attempt to obtain more carbon from these “scarce” carbon sources. 
Proteins identified as under-abundant in M. bovis and M. caprae, compared to                      
M. tuberculosis H37Rv in these pathways, form part of the feedback and regulation loops to 
keep lipid and fatty acid metabolism balanced. Lower abundance of these proteins contributes 
to the up-regulation of these pathways in the animal-adapted species. The over-abundance of 
fatty acid metabolism pathway proteins relative to M. tuberculosis may imply that M. bovis 
and M. caprae are better adapted to utilize fatty based carbon sources for energy purposes 
and biosynthesis of virulence-associated lipids during infection.  
Xenobiotic degradation 
Xenobiotic degradation is also known as drug metabolism and the reactions in these 
pathways are of particular interest relating to drug resistance in infectious diseases. Increased 
abundance of the proteins in this metabolic pathway was seen in M. bovis and M. caprae, 
relative to M. tuberculosis H37Rv. This could lead to M. bovis and M. caprae being able to 
readily get rid of foreign substances which target them within the host, for example anti-
tuberculosis drugs. M. bovis is intrinsically resistant to pyrazinamide (PZA), whereas          
M. caprae is sentivitive to PZA (Niemann, Richter et al. 2000). M. bovis and M. caprae could 
also be better suited for the harsh environment of the macrophages during infection, seeing as 




this pathway would be advantageous in detoxification of stress induced substances such as 
nitric oxide (NO) (Oliveira, Singh et al. 2012). 
Oxidative phosphorylation 
Cultures were grown in aerobic conditions which lead to ATP generation by oxidative 
phosphorylation in the electron transport chain. Host-specificity could be explained by the 
over-abundance of proteins involved in this pathway in M. bovis and M. caprae, seeing as 
infection can range from areas within the host of high to low aerobic conditions. When 
infection is in the lungs specifically, these species will have to adapt to their environment 
where they will have to compete for oxygen or adapt to the micro-aerophilic or anaerobic 
environment of the granuloma. As lower activity was observed in this pathway for                     
M. tuberculosis, one might speculate that it is better suited to the anaerobic environment of 
the human lung and is therefore more virulent.  
Ribosomal proteins 
Ribosomal proteins were found to be over-abundant and uniquely detected in            
M. bovis, compared to M. caprae and M. tuberculosis H37Rv. Increased abundance of these 
proteins could relate to the fact that whole cell lysate proteins were harvested in mid-log 
growth phase, during which time M. bovis could have been growing and replicating at a faster 
rate relative to M. caprae and M. tuberculosis. Understanding the mechanisms whereby the 
mRNA code is translated into peptides in bacteria is of great importance in fighting infectious 
diseases. Mycobacterial tolerance to antibiotics is attributed mostly to the unique properties 
of the highly impermeable cell wall and has been the main topic of studying virulence 
mechanisms (Honore, Cole 1994, Martin, Timm et al. 1990). The structures of the ribosome 
differ in human and bacterial cells, thus animal cells too, and this has led to some antibiotics 
to kill bacteria only. Many anti-tuberculosis drugs, such as streptomycin target translation or 
translation machinery (Kenney, Churchward 1994). By identifying ribosomal proteins only 




detected during the actively growing and replicating phase of M. bovis, relative to                 
M. tuberculosis and M. caprae, one can investigate the possibilities of targeting the 
mechanisms in the different steps of translation to prevent disease manifestation in hosts. In 
addition, structural studies of the complex ribosome could also lead to the understanding of 
the unique properties of Mycobacteria for e.g. slow growth (Lonnroth, Ridell 1985).  
Carbohydrate metabolism 
Proteins involved in carbohydrate metabolism were more abundant in M. caprae, 
relative to M. tuberculosis H37Rv and M. bovis. As previously mentioned, pathogenic 
Mycobacteria prefer fatty acids and cholesterol to carbohydrates as a carbon source. 
(BLOCH, SEGAL 1956)(Munoz-Elias, McKinney 2005) Estimates of the concentrations of 
potential substrates available to a pathogen in host tissues suggest that lipids and sterols are 
more abundant than carbohydrates (Cole, Brosch et al. 1998)(Marrero, Trujillo et al. 2013). 
However, Mycobacteria can co-metabolize multiple carbon sources including carbohydrates. 
The importance of carbohydrate metabolism in in vivo growth and persistence of 
Mycobacteria remains unclear (Marrero, Trujillo et al. 2013). In an attempt to understand the 
role of carbohydrate metabolism during infection, Marrero et al. showed that mutations in the 
enzymes responsible for the phosphorylation of glucose lead to M. tuberculosis H37Rv not 
being able to persist in mouse lungs (Marrero, Trujillo et al. 2013). Up-regulation of this 
pathway in M. caprae could give this species an advantage of utilizing carbohydrates 
supplied by the host during infection and could lead to better survival in goats. 
Pyrimidine metabolism 
Proteins involved in pyrimidine metabolism were less abundant in M. caprae.          
M. tuberculosis recycles bases and/or nucleosides to survive in the hostile environment 
imposed by the host via a pyrimidine salvage pathway (Villela, Basso et al. 2013)(Moffatt, 
Ashihara 2002). Enzymes involved in the pyrimidine salvage pathway might be attractive 




targets for rational drug design against TB, since this pathway is vital for all bacterial cells, 
plays an important role in the latent state and is composed of enzymes considerably different 
from those present in humans (Villela, Basso et al. 2013). Down-regulation can be attributed 
to a non-hostile environment in the culture media to which M. caprae could be more sensitive 
to or slower pyrimidine salvaging in vivo which could lead to slower conversion to latent 
phase TB in goats.  
Conclusion  
In this study the proteomes of the M. tuberculosis complex members, M. tuberculosis 
H37Rv, M. bovis and M. caprae were characterized and the variation between detected 
proteins and protein abundances explored in order to describe differences between these 
closely related strains. The influence of these proteins on various metabolic processes is 
explored and correlated with the specific or broad host range of these Mycobacteria. By 
changing the rate of expression of some of these metabolic pathways, they are able to adapt 
to their environment more readily which helps them to survive inside the hosts and cause 
severe pathogenesis if needed. 
 
   



















A major limitation of this study is our limited knowledge on how in vitro culture 
conditions translate to in vivo condition where infection, virulence and pathogenesis 
determinants may be expressed. Thus, it is possible that the proteins expressed under optimal 
culture conditions during log-growth phase will differ from the proteins expressed during 
growth within the macrophage where the pathogen experiences a multitude of stressors. 
The genome of M. caprae has not yet been annotated, and thus the proteins identified 
in the whole cell lysate and their associated functions could differ slightly from those in       
M. tuberculosis H37Rv and M. bovis. Non-synonymous single nucleotide polymorphisms 
(nsSNPs) in the genes encoding proteins in M. caprae would not be detected by MaxQuant as 
these peptides would not be present in the searched peptide databases, M. tuberculosis 
H37Rv and M. bovis.  
The LTQ Orbitrap Velos mass spectrometer has a detection limit and cannot detect 
proteins of extremely low abundance implying that unique low abundant proteins for each 
MTBC member may be missed. These proteins could form part of a pathway which is 











6.2 Future directions 
Whole cell lysate protein extracts can be taken at different time points during growth 
phases (in vivo and in vitro) to shed light on how the proteome changes during as a function 
of the nutrient status of the medium. This will contribute to understanding how the proteome 
adapts to a changing environment. 
Whole genome sequencing of M. caprae will contribute to differentiation of this 
member from the other members in the MTBC, by identification of the SNPs, RDs and large 
nucleotide polymorphisms (LSPs). Annotation of the genome may lead to the identification 
of new proteins specific to M. caprae. The genome of an M. caprae isolate will be sequenced 
on the Illumina HiSeq2000 platform using a paired-end approach, with 500 base fragment 
sizes resulting in sequences of between 350 and 550 bases. Whole genome sequencing will 
be done in collaboration with the King Abdullah University of Technology (KAUST) 
location. The depth of coverage for the sequence will be at least or above 100, this, together 
with the excellent quality of the sequencing data, will ensure a high level of confidence for 
identifying variation in the genome, relative to M. tuberculosis and M. bovis. The consensus 
sequence that will be obtained will be automatically annotated using the Rapid Annotation 
using Subsystem Technology (RAST) server.  
Future research on animal-adapted Mycobacterial species will contribute to 
preventing transmission and spread of disease to domesticated animals, free and captive 
wildlife species. Understanding the mechanisms of virulence and pathogenicity could lead to 
development of efficient vaccines and diagnostic tests for a variety of animal hosts. Better 
control regimes of zoonotic diseases could have a positive influence on the economics and 
agricultural industries of a country.  























ABLORDEY, A., SWINGS, J., HUBANS, C., CHEMLAL, K., LOCHT, C., PORTAELS, F. 
and SUPPLY, P., 2005. Multilocus variable-number tandem repeat typing of Mycobacterium 
ulcerans. Journal of clinical microbiology, 43(4), pp. 1546-1551.  
ALEXANDER, K.A., LAVER, P.N., MICHEL, A.L., WILLIAMS, M., VAN HELDEN, 
P.D., WARREN, R.M. and GEY VAN PITTIUS, N.C., 2010. Novel Mycobacterium 
tuberculosis complex pathogen, M. mungi. Emerging infectious diseases, 16(8), pp. 1296-
1299.  
AMENI, G., ASEFFA, A., ENGERS, H., YOUNG, D., GORDON, S., HEWINSON, G. and 
VORDERMEIER, M., 2007. High prevalence and increased severity of pathology of bovine 
tuberculosis in Holsteins compared to zebu breeds under field cattle husbandry in central 
Ethiopia. Clinical and vaccine immunology : CVI, 14(10), pp. 1356-1361.  
ANDREJAK, C., THOMSEN, V.O., JOHANSEN, I.S., RIIS, A., BENFIELD, T.L., 
DUHAUT, P., SORENSEN, H.T., LESCURE, F.X. and THOMSEN, R.W., 2010. 
Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. 
American journal of respiratory and critical care medicine, 181(5), pp. 514-521.  
ANGKAWANISH, T., WAJJWALKU, W., SIRIMALAISUWAN, A., 
MAHASAWANGKUL, S., KAEWSAKHORN, T., BOONSRI, K. and RUTTEN, V.P., 
2010. Mycobacterium tuberculosis infection of domesticated Asian elephants, Thailand. 
Emerging infectious diseases, 16(12), pp. 1949-1951.  
BERCOVIER, H. and VINCENT, V., 2001. Mycobacterial infections in domestic and wild 
animals due to Mycobacterium marinum, M. fortuitum, M. chelonae, M. porcinum, M. 
farcinogenes, M. smegmatis, M. scrofulaceum, M. xenopi, M. kansasii, M. simiae and M. 
genavense. Revue scientifique et technique (International Office of Epizootics), 20(1), pp. 
265-290.  
BERG, S., GARCIA-PELAYO, M.C., MULLER, B., HAILU, E., ASIIMWE, B., KREMER, 
K., DALE, J., BONIOTTI, M.B., RODRIGUEZ, S., HILTY, M., RIGOUTS, L., FIRDESSA, 
R., MACHADO, A., MUCAVELE, C., NGANDOLO, B.N., BRUCHFELD, J., 
BOSCHIROLI, L., MULLER, A., SAHRAOUI, N., PACCIARINI, M., CADMUS, S., 
JOLOBA, M., VAN SOOLINGEN, D., MICHEL, A.L., DJONNE, B., ARANAZ, A., 
ZINSSTAG, J., VAN HELDEN, P., PORTAELS, F., KAZWALA, R., KALLENIUS, G., 
HEWINSON, R.G., ASEFFA, A., GORDON, S.V. and SMITH, N.H., 2011. African 2, a 
clonal complex of Mycobacterium bovis epidemiologically important in East Africa. Journal 
of Bacteriology, 193(3), pp. 670-678.  
BLOCH, H. and SEGAL, W., 1956. Biochemical differentiation of Mycobacterium 
tuberculosis grown in vivo and in vitro. Journal of Bacteriology, 72(2), pp. 132-141.  
BRAGG, R.R., HUCHZERMEYER, H.F. and HANISCH, M.A., 1990. Mycobacterium 
fortuitum isolated from three species of fish in South Africa. The Onderstepoort journal of 
veterinary research, 57(1), pp. 101-102.  
BRENNAN, P.J. and NIKAIDO, H., 1995. The envelope of mycobacteria. Annual Review of 
Biochemistry, 64, pp. 29-63.  




BROSCH, R., GORDON, S.V., MARMIESSE, M., BRODIN, P., BUCHRIESER, C., 
EIGLMEIER, K., GARNIER, T., GUTIERREZ, C., HEWINSON, G., KREMER, K., 
PARSONS, L.M., PYM, A.S., SAMPER, S., VAN SOOLINGEN, D. and COLE, S.T., 2002. 
A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proceedings of 
the National Academy of Sciences of the United States of America, 99(6), pp. 3684-3689.  
BROWN, T.H., 1985. The rapidly growing mycobacteria--Mycobacterium fortuitum and 
Mycobacterium chelonei. Infection control : IC, 6(7), pp. 283-288.  
CAMACHO, L.R., CONSTANT, P., RAYNAUD, C., LANEELLE, M.A., TRICCAS, J.A., 
GICQUEL, B., DAFFE, M. and GUILHOT, C., 2001. Analysis of the phthiocerol 
dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in 
the cell wall permeability barrier. The Journal of biological chemistry, 276(23), pp. 19845-
19854.  
CHAMOISEAU, G., 1973. "Mycobacterium farcinogenes" causal agent of bovine farcy in 
Africa (author's transl). Annales de Microbiologie, 124(2), pp. 215-222.  
CHIHOTA, V.N., MULLER, B., MLAMBO, C.K., PILLAY, M., TAIT, M., STREICHER, 
E.M., MARAIS, E., VAN DER SPUY, G.D., HANEKOM, M., COETZEE, G., TROLLIP, 
A., HAYES, C., BOSMAN, M.E., GEY VAN PITTIUS, N.C., VICTOR, T.C., VAN 
HELDEN, P.D. and WARREN, R.M., 2012. Population structure of multi- and extensively 
drug-resistant Mycobacterium tuberculosis strains in South Africa. Journal of clinical 
microbiology, 50(3), pp. 995-1002.  
COLE, S.T., BROSCH, R., PARKHILL, J., GARNIER, T., CHURCHER, C., HARRIS, D., 
GORDON, S.V., EIGLMEIER, K., GAS, S., BARRY, C.E.,3RD, TEKAIA, F., BADCOCK, 
K., BASHAM, D., BROWN, D., CHILLINGWORTH, T., CONNOR, R., DAVIES, R., 
DEVLIN, K., FELTWELL, T., GENTLES, S., HAMLIN, N., HOLROYD, S., HORNSBY, 
T., JAGELS, K., KROGH, A., MCLEAN, J., MOULE, S., MURPHY, L., OLIVER, K., 
OSBORNE, J., QUAIL, M.A., RAJANDREAM, M.A., ROGERS, J., RUTTER, S., 
SEEGER, K., SKELTON, J., SQUARES, R., SQUARES, S., SULSTON, J.E., TAYLOR, K., 
WHITEHEAD, S. and BARRELL, B.G., 1998. Deciphering the biology of Mycobacterium 
tuberculosis from the complete genome sequence. Nature, 393(6685), pp. 537-544.  
CONVERSE, S.E., MOUGOUS, J.D., LEAVELL, M.D., LEARY, J.A., BERTOZZI, C.R. 
and COX, J.S., 2003. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium 
tuberculosis virulence. Proceedings of the National Academy of Sciences of the United States 
of America, 100(10), pp. 6121-6126.  
COOK, J.L., 2010. Nontuberculous mycobacteria: opportunistic environmental pathogens for 
predisposed hosts. British medical bulletin, 96, pp. 45-59.  
COSIVI, O., GRANGE, J.M., DABORN, C.J., RAVIGLIONE, M.C., FUJIKURA, T., 
COUSINS, D., ROBINSON, R.A., HUCHZERMEYER, H.F., DE KANTOR, I. and 
MESLIN, F.X., 1998. Zoonotic tuberculosis due to Mycobacterium bovis in developing 
countries. Emerging infectious diseases, 4(1), pp. 59-70.  




COX, J. and MANN, M., 2008. MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature 
biotechnology, 26(12), pp. 1367-1372.  
COX, J.S., CHEN, B., MCNEIL, M. and JACOBS, W.R.,JR, 1999. Complex lipid 
determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature, 
402(6757), pp. 79-83.  
CVETNIC, Z., KATALINIC-JANKOVIC, V., SOSTARIC, B., SPICIC, S., OBROVAC, M., 
MARJANOVIC, S., BENIC, M., KIRIN, B.K. and VICKOVIC, I., 2007. Mycobacterium 
caprae in cattle and humans in Croatia. The international journal of tuberculosis and lung 
disease : the official journal of the International Union against Tuberculosis and Lung 
Disease, 11(6), pp. 652-658.  
DE GROOTE, M.A. and HUITT, G., 2006. Infections Due to Rapidly Growing 
Mycobacteria. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America, 42, pp. 1756-1763.  
DE LA RUA-DOMENECH, R., GOODCHILD, A.T., VORDERMEIER, H.M., 
HEWINSON, R.G., CHRISTIANSEN, K.H. and CLIFTON-HADLEY, R.S., 2006. Ante 
mortem diagnosis of tuberculosis in cattle: a review of the tuberculin tests, gamma-interferon 
assay and other ancillary diagnostic techniques. Research in veterinary science, 81(2), pp. 
190-210.  
DE SOUZA, G.A., ARNTZEN, M.O., FORTUIN, S., SCHURCH, A.C., MALEN, H., 
MCEVOY, C.R., VAN SOOLINGEN, D., THIEDE, B., WARREN, R.M. and WIKER, 
H.G., 2011. Proteogenomic analysis of polymorphisms and gene annotation divergences in 
prokaryotes using a clustered mass spectrometry-friendly database. Molecular & cellular 
proteomics : MCP, 10(1), pp. M110.002527.  
DEN BOON, S., VAN LILL, S.W., BORGDORFF, M.W., ENARSON, D.A., VERVER, S., 
BATEMAN, E.D., IRUSEN, E., LOMBARD, C.J., WHITE, N.W., DE VILLIERS, C. and 
BEYERS, N., 2007. High prevalence of tuberculosis in previously treated patients, Cape 
Town, South Africa. Emerging infectious diseases, 13(8), pp. 1189-1194.  
DREWE, J.A., EAMES, K.T., MADDEN, J.R. and PEARCE, G.P., 2011. Integrating contact 
network structure into tuberculosis epidemiology in meerkats in South Africa: Implications 
for control. Preventive veterinary medicine, 101(1-2), pp. 113-120.  
FALKINHAM, J.O., 2010. Impact of human activities on the ecology of nontuberculous 
mycobacteria. Future microbiology, 5(6), pp. 951-960.  
FALKINHAM, J.O.,3RD, 2011. Nontuberculous mycobacteria from household plumbing of 
patients with nontuberculous mycobacteria disease. Emerging infectious diseases, 17(3), pp. 
419-424.  
GARNIER, T., EIGLMEIER, K., CAMUS, J.C., MEDINA, N., MANSOOR, H., PRYOR, 
M., DUTHOY, S., GRONDIN, S., LACROIX, C., MONSEMPE, C., SIMON, S., HARRIS, 
B., ATKIN, R., DOGGETT, J., MAYES, R., KEATING, L., WHEELER, P.R., PARKHILL, 
J., BARRELL, B.G., COLE, S.T., GORDON, S.V. and HEWINSON, R.G., 2003. The 




complete genome sequence of Mycobacterium bovis. Proceedings of the National Academy 
of Sciences of the United States of America, 100(13), pp. 7877-7882.  
GEY VAN PITTIUS, N.C., PERRETT, K.D., MICHEL, A.L., KEET, D.F., HLOKWE, T., 
STREICHER, E.M., WARREN, R.M. and VAN HELDEN, P.D., 2012. Infection of African 
buffalo (Syncerus caffer) by oryx bacillus, a rare member of the antelope clade of the 
Mycobacterium tuberculosis complex. Journal of wildlife diseases, 48(4), pp. 849-857.  
GEY VAN PITTIUS, N.C., SAMPSON, S.L., LEE, H., KIM, Y., VAN HELDEN, P.D. and 
WARREN, R.M., 2006. Evolution and expansion of the Mycobacterium tuberculosis PE and 
PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene 
cluster regions. BMC evolutionary biology, 6, pp. 95.  
GEY VAN PITTIUS, N.C., VAN HELDEN, P.D. and WARREN, R.M., 2012. 
Characterization of Mycobacterium orygis. Emerging infectious diseases, 18(10), pp. 1708-
1709.  
GILLESPIE, J.J., WATTAM, A.R., CAMMER, S.A., GABBARD, J.L., SHUKLA, M.P., 
DALAY, O., DRISCOLL, T., HIX, D., MANE, S.P., MAO, C., NORDBERG, E.K., SCOTT, 
M., SCHULMAN, J.R., SNYDER, E.E., SULLIVAN, D.E., WANG, C., WARREN, A., 
WILLIAMS, K.P., XUE, T., YOO, H.S., ZHANG, C., ZHANG, Y., WILL, R., KENYON, 
R.W. and SOBRAL, B.W., 2011. PATRIC: the comprehensive bacterial bioinformatics 
resource with a focus on human pathogenic species. Infection and immunity, 79(11), pp. 
4286-4298.  
GRANDONI, J.A., MARTA, P.T. and SCHLOSS, J.V., 1998. Inhibitors of branched-chain 
amino acid biosynthesis as potential antituberculosis agents. The Journal of antimicrobial 
chemotherapy, 42(4), pp. 475-482.  
GRIFFITH, D.E., AKSAMIT, T., BROWN-ELLIOTT, B.A., CATANZARO, A., DALEY, 
C., GORDIN, F., HOLLAND, S.M., HORSBURGH, R., HUITT, G., IADEMARCO, M.F., 
ISEMAN, M., OLIVIER, K., RUOSS, S., VON REYN, C.F., WALLACE, R.J.,JR, 
WINTHROP, K., ATS MYCOBACTERIAL DISEASES SUBCOMMITTEE, AMERICAN 
THORACIC SOCIETY and INFECTIOUS DISEASE SOCIETY OF AMERICA, 2007. An 
official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous 
mycobacterial diseases. American journal of respiratory and critical care medicine, 175(4), 
pp. 367-416.  
GUMI, B., SCHELLING, E., BERG, S., FIRDESSA, R., ERENSO, G., MEKONNEN, W., 
HAILU, E., MELESE, E., HUSSEIN, J., ASEFFA, A. and ZINSSTAG, J., 2012. Zoonotic 
transmission of tuberculosis between pastoralists and their livestock in South-East Ethiopia. 
EcoHealth, 9(2), pp. 139-149.  
HANEKOM, M., VAN DER SPUY, G.D., GEY VAN PITTIUS, N.C., MCEVOY, C.R., 
NDABAMBI, S.L., VICTOR, T.C., HOAL, E.G., VAN HELDEN, P.D. and WARREN, 
R.M., 2007. Evidence that the spread of Mycobacterium tuberculosis strains with the Beijing 
genotype is human population dependent. Journal of clinical microbiology, 45(7), pp. 2263-
2266.  




HATHERILL, M., HAWKRIDGE, T., WHITELAW, A., TAMERIS, M., MAHOMED, H., 
MOYO, S., HANEKOM, W. and HUSSEY, G., 2006. Isolation of non-tuberculous 
mycobacteria in children investigated for pulmonary tuberculosis. PloS one, 1, pp. e21.  
HOLLAND, S.M., 2001. Nontuberculous mycobacteria. The American Journal of the 
Medical Sciences, 321(1), pp. 49-55.  
HONORE, N. and COLE, S.T., 1994. Streptomycin resistance in mycobacteria. 
Antimicrobial Agents and Chemotherapy, 38(2), pp. 238-242.  
HUARD, R.C., FABRE, M., DE HAAS, P., LAZZARINI, L.C., VAN SOOLINGEN, D., 
COUSINS, D. and HO, J.L., 2006. Novel genetic polymorphisms that further delineate the 
phylogeny of the Mycobacterium tuberculosis complex. Journal of Bacteriology, 188(12), pp. 
4271-4287.  
ISEMAN, M.D. and MARRAS, T.K., 2008. The importance of nontuberculous 
mycobacterial lung disease. American journal of respiratory and critical care medicine, 
178(10), pp. 999-1000.  
KAMERBEEK, J., SCHOULS, L., KOLK, A., VAN AGTERVELD, M., VAN 
SOOLINGEN, D., KUIJPER, S., BUNSCHOTEN, A., MOLHUIZEN, H., SHAW, R., 
GOYAL, M. and VAN EMBDEN, J., 1997. Simultaneous detection and strain differentiation 
of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of clinical 
microbiology, 35(4), pp. 907-914.  
KANEENE, J.B. and THOEN, C.O., 2004. Tuberculosis. Journal of the American Veterinary 
Medical Association, 224(5), pp. 685-691.  
KANEHISA, M. and GOTO, S., 2000. KEGG: kyoto encyclopedia of genes and genomes. 
Nucleic acids research, 28(1), pp. 27-30.  
KANKYA, C., MUWONGE, A., DJONNE, B., MUNYEME, M., OPUDA-ASIBO, J., 
SKJERVE, E., OLOYA, J., EDVARDSEN, V. and JOHANSEN, T.B., 2011. Isolation of 
non-tuberculous mycobacteria from pastoral ecosystems of Uganda: public health 
significance. BMC public health, 11, pp. 320-2458-11-320.  
KARNE, S.S., SANGLE, S.A., KIYAWAT, D.S., DHARMASHALE, S.N., KADAM, D.B. 
and BHARDWAJ, R.S., 2012. Mycobacterium avium-intracellulare brain abscess in HIV-
positive patient. Annals of Indian Academy of Neurology, 15(1), pp. 54-55.  
KATALE, B.Z., MBUGI, E.V., KENDAL, S., FYUMAGWA, R.D., KIBIKI, G.S., 
GODFREY-FAUSSETT, P., KEYYU, J.D., VAN HELDEN, P. and MATEE, M.I., 2012. 
Bovine tuberculosis at the human-livestock-wildlife interface: Is it a public health problem in 
Tanzania? A review. The Onderstepoort journal of veterinary research, 79(2), pp. E1-8.  
KATOCH, V.M., 2004. Infections due to non-tuberculous mycobacteria (NTM). The Indian 
journal of medical research, 120(4), pp. 290-304.  
KAUFMANN, S.H., 2002. Protection against tuberculosis: cytokines, T cells, and 
macrophages. Annals of the Rheumatic Diseases, 61 Suppl 2, pp. ii54-8.  




KENNEY, T.J. and CHURCHWARD, G., 1994. Cloning and sequence analysis of the rpsL 
and rpsG genes of Mycobacterium smegmatis and characterization of mutations causing 
resistance to streptomycin. Journal of Bacteriology, 176(19), pp. 6153-6156.  
KOLATTUKUDY, P.E., FERNANDES, N.D., AZAD, A.K., FITZMAURICE, A.M. and 
SIRAKOVA, T.D., 1997. Biochemistry and molecular genetics of cell-wall lipid biosynthesis 
in mycobacteria. Molecular microbiology, 24(2), pp. 263-270.  
LOBUE, P.A., ENARSON, D.A. and THOEN, C.O., 2010. Tuberculosis in humans and 
animals: an overview. The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease, 14(9), pp. 1075-
1078.  
LONNROTH, L. and RIDELL, M., 1985. Analyses of ribosomal proteins from mycobacteria 
with particular reference to the beta antigen. FEMS Microbiology Letters, 27, pp. 203-207.  
MARRERO, J., TRUJILLO, C., RHEE, K.Y. and EHRT, S., 2013. Glucose phosphorylation 
is required for Mycobacterium tuberculosis persistence in mice. PLoS pathogens, 9(1), pp. 
e1003116.  
MARTIN, C., TIMM, J., RAUZIER, J., GOMEZ-LUS, R., DAVIES, J. and GICQUEL, B., 
1990. Transposition of an antibiotic resistance element in mycobacteria. Nature, 345(6277), 
pp. 739-743.  
MCADAM, R.A., WEISBROD, T.R., MARTIN, J., SCUDERI, J.D., BROWN, A.M., 
CIRILLO, J.D., BLOOM, B.R. and JACOBS, W.R.,JR, 1995. In vivo growth characteristics 
of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by 
transposon mutagenesis. Infection and immunity, 63(3), pp. 1004-1012.  
MICHEL, A.L., COETZEE, M.L., KEET, D.F., MARE, L., WARREN, R., COOPER, D., 
BENGIS, R.G., KREMER, K. and VAN HELDEN, P., 2009. Molecular epidemiology of 
Mycobacterium bovis isolates from free-ranging wildlife in South African game reserves. 
Veterinary microbiology, 133(4), pp. 335-343.  
MICHEL, A.L., DE KLERK, L.M., GEY VAN PITTIUS, N.C., WARREN, R.M. and VAN 
HELDEN, P.D., 2007. Bovine tuberculosis in African buffaloes: observations regarding 
Mycobacterium bovis shedding into water and exposure to environmental mycobacteria. 
BMC veterinary research, 3, pp. 23.  
MICHEL, A.L., MULLER, B. and VAN HELDEN, P.D., 2010. Mycobacterium bovis at the 
animal-human interface: a problem, or not? Veterinary microbiology, 140(3-4), pp. 371-381.  
MOFFATT, B.A. and ASHIHARA, H., 2002. Purine and pyrimidine nucleotide synthesis 
and metabolism. The Arabidopsis book / American Society of Plant Biologists, 1, pp. e0018.  
MONTALI, R.J., MIKOTA, S.K. and CHENG, L.I., 2001. Mycobacterium tuberculosis in 
zoo and wildlife species. Revue scientifique et technique (International Office of Epizootics), 
20(1), pp. 291-303.  




MOORE, J.E., KRUIJSHAAR, M.E., ORMEROD, L.P., DROBNIEWSKI, F. and 
ABUBAKAR, I., 2010. Increasing reports of non-tuberculous mycobacteria in England, 
Wales and Northern Ireland, 1995-2006. BMC public health, 10, pp. 612-2458-10-612.  
MULLER, B., DE KLERK-LORIST, L.M., HENTON, M.M., LANE, E., PARSONS, S., 
GEY VAN PITTIUS, N.C., KOTZE, A., VAN HELDEN, P.D. and TANNER, M., 2011. 
Mixed infections of Corynebacterium pseudotuberculosis and non-tuberculous mycobacteria 
in South African antelopes presenting with tuberculosis-like lesions. Veterinary 
microbiology, 147(3-4), pp. 340-345.  
MULLER, B., STEINER, B., BONFOH, B., FANE, A., SMITH, N.H. and ZINSSTAG, J., 
2008. Molecular characterisation of Mycobacterium bovis isolated from cattle slaughtered at 
the Bamako abattoir in Mali. BMC veterinary research, 4, pp. 26-6148-4-26.  
MUNOZ-ELIAS, E.J. and MCKINNEY, J.D., 2005. Mycobacterium tuberculosis isocitrate 
lyases 1 and 2 are jointly required for in vivo growth and virulence. Nature medicine, 11(6), 
pp. 638-644.  
MUNYEME, M., RIGOUTS, L., SHAMPUTA, I.C., MUMA, J.B., TRYLAND, M., 
SKJERVE, E. and DJONNE, B., 2009. Isolation and characterization of Mycobacterium 
bovis strains from indigenous Zambian cattle using Spacer oligonucleotide typing technique. 
BMC microbiology, 9, pp. 144-2180-9-144.  
MUYOYETA, M., DE HAAS, P.E., MUELLER, D.H., VAN HELDEN, P.D., MWENGE, 
L., SCHAAP, A., KRUGER, C., GEY VAN PITTIUS, N.C., LAWRENCE, K., BEYERS, 
N., GODFREY-FAUSSETT, P. and AYLES, H., 2010. Evaluation of the Capilia TB assay 
for culture confirmation of Mycobacterium tuberculosis infections in Zambia and South 
Africa. Journal of clinical microbiology, 48(10), pp. 3773-3775.  
NIEMANN, S., RICHTER, E. and RUSCH-GERDES, S., 2000. Differentiation among 
members of the Mycobacterium tuberculosis complex by molecular and biochemical features: 
evidence for two pyrazinamide-susceptible subtypes of M. bovis. Journal of clinical 
microbiology, 38(1), pp. 152-157.  
OLIVEIRA, A., SINGH, S., BIDON-CHANAL, A., FORTI, F., MARTI, M.A., BOECHI, L., 
ESTRIN, D.A., DIKSHIT, K.L. and LUQUE, F.J., 2012. Role of PheE15 gate in ligand entry 
and nitric oxide detoxification function of Mycobacterium tuberculosis truncated hemoglobin 
N. PloS one, 7(11), pp. e49291.  
PARSONS, S.D.C., DREWE, J.A., GEY VAN PITTIUS, N.C., WARREN, R.M. and VAN 
HELDEN, P.D., 2013. A novel pathogen, Mycobacterium suricattae, is the cause of 
tuberculosis in meerkats (Suricata suricatta) in South Africa. Emerging infectious diseases, 
19(12), pp. 2004-2007.  
PARSONS, S., SMITH, S.G., MARTINS, Q., HORSNELL, W.G., GOUS, T.A., 
STREICHER, E.M., WARREN, R.M., VAN HELDEN, P.D. and GEY VAN PITTIUS, N.C., 
2008. Pulmonary infection due to the dassie bacillus (Mycobacterium tuberculosis complex 
sp.) in a free-living dassie (rock hyrax-Procavia capensis) from South Africa. Tuberculosis 
(Edinburgh, Scotland), 88(1), pp. 80-83.  




PARSONS, S.D., GOUS, T.A., WARREN, R.M. and VAN HELDEN, P.D., 2008. 
Pulmonary Mycobacterium tuberculosis (Beijing strain) infection in a stray dog. Journal of 
the South African Veterinary Association, 79(2), pp. 95-98.  
PARSONS, S.D., WARREN, R.M., OTTENHOFF, T.H., GEY VAN PITTIUS, N.C. and 
VAN HELDEN, P.D., 2012. Detection of Mycobacterium tuberculosis infection in dogs in a 
high-risk setting. Research in veterinary science, 92(3), pp. 414-419.  
PETRINI, B., 2006. Mycobacterium abscessus: an emerging rapid-growing potential 
pathogen. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 
114(5), pp. 319-328.  
PFYFFER, G.E., AUCKENTHALER, R., VAN EMBDEN, J.D. and VAN SOOLINGEN, 
D., 1998. Mycobacterium canettii, the smooth variant of M. tuberculosis, isolated from a 
Swiss patient exposed in Africa. Emerging infectious diseases, 4(4), pp. 631-634.  
PHILLIPS, M.S. and VON REYN, C.F., 2001. Nosocomial infections due to nontuberculous 
mycobacteria. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America, 33(8), pp. 1363-1374.  
PREVOTS, D.R., SHAW, P.A., STRICKLAND, D., JACKSON, L.A., RAEBEL, M.A., 
BLOSKY, M.A., MONTES DE OCA, R., SHEA, Y.R., SEITZ, A.E., HOLLAND, S.M. and 
OLIVIER, K.N., 2010. Nontuberculous mycobacterial lung disease prevalence at four 
integrated health care delivery systems. American journal of respiratory and critical care 
medicine, 182(7), pp. 970-976.  
REED, M.B., DOMENECH, P., MANCA, C., SU, H., BARCZAK, A.K., KREISWIRTH, 
B.N., KAPLAN, G. and BARRY, C.E.,3RD, 2004. A glycolipid of hypervirulent tuberculosis 
strains that inhibits the innate immune response. Nature, 431(7004), pp. 84-87.  
RODRIGUEZ, S., BEZOS, J., ROMERO, B., DE JUAN, L., ALVAREZ, J., 
CASTELLANOS, E., MOYA, N., LOZANO, F., JAVED, M.T., SAEZ-LLORENTE, J.L., 
LIEBANA, E., MATEOS, A., DOMINGUEZ, L., ARANAZ, A. and SPANISH NETWORK 
ON SURVEILLANCE AND MONITORING OF ANIMAL TUBERCULOSIS, 2011. 
Mycobacterium caprae infection in livestock and wildlife, Spain. Emerging infectious 
diseases, 17(3), pp. 532-535.  
ROUSSEAU, C., WINTER, N., PIVERT, E., BORDAT, Y., NEYROLLES, O., AVE, P., 
HUERRE, M., GICQUEL, B. and JACKSON, M., 2004. Production of phthiocerol 
dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive 
nitrogen intermediates produced by macrophages and modulates the early immune response 
to infection. Cellular microbiology, 6(3), pp. 277-287.  
SHAMAEI, M., MARJANI, M., FARNIA, P., TABARSI, P. and MANSOURI, D., 2010. 
Human infections due to Mycobacterium lentiflavum: first report in Iran. Iranian journal of 
microbiology, 2(1), pp. 27-29.  
SIMONS, S., VAN INGEN, J., HSUEH, P.R., VAN HUNG, N., DEKHUIJZEN, P.N., 
BOEREE, M.J. and VAN SOOLINGEN, D., 2011. Nontuberculous mycobacteria in 
respiratory tract infections, eastern Asia. Emerging infectious diseases, 17(3), pp. 343-349.  




SKINNER, M.A., WEDLOCK, D.N. and BUDDLE, B.M., 2001. Vaccination of animals 
against Mycobacterium bovis. Revue scientifique et technique (International Office of 
Epizootics), 20(1), pp. 112-132.  
SMITH, M.I., YATSUNENKO, T., MANARY, M.J., TREHAN, I., MKAKOSYA, R., 
CHENG, J., KAU, A.L., RICH, S.S., CONCANNON, P., MYCHALECKYJ, J.C., LIU, J., 
HOUPT, E., LI, J.V., HOLMES, E., NICHOLSON, J., KNIGHTS, D., URSELL, L.K., 
KNIGHT, R. and GORDON, J.I., 2013. Gut microbiomes of Malawian twin pairs discordant 
for kwashiorkor. Science (New York, N.Y.), 339(6119), pp. 548-554.  
SMITH, N.H., HEWINSON, R.G., KREMER, K., BROSCH, R. and GORDON, S.V., 2009. 
Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nature 
reviews.Microbiology, 7(7), pp. 537-544.  
SØRENSEN, A.L., NAGAI, S., HOUEN, G., ANDERSEN, P. and ANDERSEN, A.B., 1995. 
Purification and characterization of a low-molecular-mass T-cell antigen secreted by 
Mycobacterium tuberculosis.. Infection and Immunity, 63(5), pp. 1710-1717.  
STREICHER, E.M., VICTOR, T.C., VAN DER SPUY, G., SOLA, C., RASTOGI, N., VAN 
HELDEN, P.D. and WARREN, R.M., 2007. Spoligotype signatures in the Mycobacterium 
tuberculosis complex. Journal of clinical microbiology, 45(1), pp. 237-240.  
VAN EMBDEN, J.D., CAVE, M.D., CRAWFORD, J.T., DALE, J.W., EISENACH, K.D., 
GICQUEL, B., HERMANS, P., MARTIN, C., MCADAM, R. and SHINNICK, T.M., 1993. 
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: 
recommendations for a standardized methodology. Journal of clinical microbiology, 31(2), 
pp. 406-409.  
VAN HELDEN, P.D., PARSONS, S.D. and GEY VAN PITTIUS, N.C., 2009. 'Emerging' 
mycobacteria in South Africa. Journal of the South African Veterinary Association, 80(4), pp. 
210-214.  
VAN INGEN, J., BOEREE, M.J., VAN SOOLINGEN, D. and MOUTON, J.W., 2012. 
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug 
resistance updates : reviews and commentaries in antimicrobial and anticancer 
chemotherapy, 15(3), pp. 149-161.  
VAN INGEN, J., RAHIM, Z., MULDER, A., BOEREE, M.J., SIMEONE, R., BROSCH, R. 
and VAN SOOLINGEN, D., 2012. Characterization of Mycobacterium orygis as M. 
tuberculosis complex subspecies. Emerging infectious diseases, 18(4), pp. 653-655.  
VILLELA, A.D., BASSO, L.A. and SANTOS, D.S., 2013. Biochemical Characterization of 
Uracil Phosphoribosyltransferase from Mycobacterium tuberculosis. PLoS One, 8(2), pp. 
e56445.  
WARREN, R.M., GEY VAN PITTIUS, N.C., BARNARD, M., HESSELING, A., 
ENGELKE, E., DE KOCK, M., GUTIERREZ, M.C., CHEGE, G.K., VICTOR, T.C., HOAL, 
E.G. and VAN HELDEN, P.D., 2006a. Differentiation of Mycobacterium tuberculosis 
complex by PCR amplification of genomic regions of difference. The international journal of 




tuberculosis and lung disease : the official journal of the International Union against 
Tuberculosis and Lung Disease, 10(7), pp. 818-822.  
WARREN, R.M., GEY VAN PITTIUS, N.C., BARNARD, M., HESSELING, A., 
ENGELKE, E., DE KOCK, M., GUTIERREZ, M.C., CHEGE, G.K., VICTOR, T.C., HOAL, 
E.G. and VAN HELDEN, P.D., 2006b. Differentiation of Mycobacterium tuberculosis 
complex by PCR amplification of genomic regions of difference. The international journal of 
tuberculosis and lung disease : the official journal of the International Union against 
Tuberculosis and Lung Disease, 10(7), pp. 818-822.  
WHITTINGTON, R.J., MARSH, I.B. and REDDACLIFF, L.A., 2005. Survival of 
Mycobacterium avium subsp. paratuberculosis in dam water and sediment. Applied and 
Environmental Microbiology, 71(9), pp. 5304-5308.  
YEW, W.W., SOTGIU, G. and MIGLIORI, G.B., 2011. Update in tuberculosis and 
nontuberculous mycobacterial disease 2010. American journal of respiratory and critical 
care medicine, 184(2), pp. 180-185.  
 
  
























Culture media composition 
Table A1: Difco
TM
 Middlebrook 7H9 medium supplemented with ADC 
Composition Source 
0.47% (w/v) Middlebrook 7H9 Beckton-Dickson (BD) Biosciences, USA 
0.2% (v/v) glycerol Merck, Germany 
0.1% (v/v) Tween®-80 
10.0% (v/v) ADC* 
90.0 ml milliQ water 
Sigma-Aldrich, USA 




Middlebrook 7H9 medium supplemented with DC 
Composition Source 
0.47% (w/v) Middlebrook 7H9 Beckton-Dickson (BD) Biosciences, USA 
0.2% (v/v) glycerol Merck, Germany 
0.1% (v/v) Tween®-80 
10.0% (v/v) DC* 
90.0 ml milliQ water 
Sigma-Aldrich, USA 




 Middlebrook 7H10 base supplemented with ADC 
Composition Source 
1.9% (w/v) Middlebrook 7H10 Beckton-Dickson (BD) Biosciences, USA 
0.5% (v/v) glycerol Merck, Germany 
10.0% (v/v) ADC* 
90.0 ml milliQ water 
 
*See Table A4 for composition. 
 




Table A4: Supplements of culture media 
Supplement Stock 
concentration 
Sterilization Storage Source 
Glycerol 100% (v/v) Filtered 4ºC Merck, 
Germany 




0.5% (v/v) albumin 











Whole cell lysate protein extraction solution 
Table A5: Lysis buffer 
Composition Source 
50 µl 1M Tris (pH 7.4) Merck, Germany 
3 µl 20% Tween-80 Sigma-Aldrich, USA 
200 µl 20 µl/1 ml Protease inhibitors set III Merck, Germany 










Table A6: Laemmli sample buffer (4x) 
Composition Source 
2.4 ml 1M Tris (pH 6.8) Merck, Germany 
0.8 g SDS 
4.0 ml 100% glycerol 




1.0 ml β-mercapto-ethanol 
2.8 ml milliQ water 
Sigma-Aldrich, USA 
Laemmli buffer was stored at room temperature and added to samples in a flow-hood. 
 
 
In-gel trypsin digest solutions 
The following solutions were freshly prepared for each subset of 40 samples. 
Table A7: In-gel trypsin digest solutions 
Solution Composition Source 
50% ACN 
 
25 mM ABC 
10 ml 100% ACN 
10 ml milliQ water 
0.08 g ABC 





50 mM ABC 
 
10 mM DTT 
 
55 mM IAA 
0.12 g ABC 
30 ml milliQ water 
0.031 g DTT 
20 ml 25 mM ABC 
0.2 g IAA 







10 ng/ µl Trypsin 20 µl 1µl/10 µl Trypsin 
180 µl 50 mM ABC 
Promega, USA 
Sigma-Aldrich, USA 




Stage-tip activation solutions 
The following solutions were freshly prepared for each subset of 40 samples. 
Table A8: Stage-tip activation solutions 
Solution Composition Source 
5% Formic acid (FA) 
 
80% ACN, 5% FA 
250 µl 100% Formic acid 
4,750 ml milliQ water 
12.0 ml ACN 
3.0 ml milliQ water 
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